Scott Kopetz, M.D., Ph.D., FACP

Peer-Reviewed Articles

1. Singh M, Morris VK, Bandey IN, Hong DS, Kopetz S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends Cancer. e-Pub 2024. PMID: 38821852.
2. Zhu Y, Koleilat MKI, Roszik J, Kwong MK, Wang Z, Maru DM, Kopetz S, Kwong LN. A Gold Standard-Derived Modular Barcoding Approach to Cancer Transcriptomics. Cancers (Basel) 16(10), 2024. e-Pub 2024. PMID: 38791964.
3. Bhutiani N, Yousef MMG, Yousef A, Zeineddine M, Knafl M, Ratliff O, Fernando UP, Turin A, Zeineddine FA, Jin J, Alfaro-Munoz K, Goldstein D, Chang GJ, Kopetz S, Shen JP, Uppal A. Automated, High-Throughput Platform to Generate a High-Reliability, Comprehensive Rectal Cancer Database. JCO Clin Cancer Inform 8:e2300219, 2024. PMID: 38759125.
4. Yaeger R, Uboha NV, Pelster MS, Bekaii-Saab TS, Barve M, Saltzman J, Sabari JK, Peguero JA, Paulson AS, Jänne PA, Cruz-Correa M, Anderes K, Velastegui K, Yan X, Der-Torossian H, Klempner SJ, Kopetz SE. Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. Cancer Discov:OF1-OF12. e-Pub 2024. PMID: 38587856.
5. Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, Bestvina CM, Kopetz S, Falchook GS, Langer C, Krauss J, Puri S, Cardona P, Chan E, Varrieur T, Mukundan L, Anderson A, Tran Q, Hong DS. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. e-Pub 2024. PMID: 38177853.
6. Yazdani A, Lenz HJ, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanof H, Hadi R, Samiei E, Venook AP, Ratain MJ, Rashid N, Vincent BG, Qu X, Wen Y, Kosorok M, Symmans WF, Shen JPYC, Lee MS, Kopetz S, Nixon AB, Bertagnolli MM, Perou CM, Innocenti F. Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy. Res Sq, 2023. e-Pub 2023. PMID: 38168324.
7. Stemmer A, Margalit O, Serpas V, Strauss G, Thomas J, Shah P, Tau N, Levanon K, Shacham-Shmueli E, Kopetz S, Overman M, Boursi B. Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers. Eur J Cancer 198:113495. e-Pub 2023. PMID: 38157568.
8. Lin K, Chowdhury S, Zeineddine MA, Zeineddine FA, Hornstein NJ, Villarreal OE, Maru DM, Haymaker CL, Vauthey JN, Chang GJ, Bogatenkova E, Menter D, Kopetz S, Shen JP. Identification of colorectal cancer cell stemness from single-cell RNA sequencing. Mol Cancer Res. e-Pub 2023. PMID: 38156967.
9. Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. PMID: 38085001.
10. Zhang X, Irajizad E, Hoffman KL, Fahrmann JF, Li F, Seo YD, Browman GJ, Dennison JB, Vykoukal J, Luna PN, Siu W, Wu R, Murage E, Ajami NJ, McQuade JL, Wargo JA, Long JP, Do KA, Lampe JW, Basen-Engquist KM, Okhuysen PC, Kopetz S, Hanash SM, Petrosino JF, Scheet P, Daniel CR. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. EBioMedicine:104873. e-Pub 2023. PMID: 38040541.
11. Raghav KPS, Loree JM, Kopetz S. PRESSING need of precision care in HER2-positive CRC: The ELEPHANT in the room. Clin Cancer Res. e-Pub 2023. PMID: 37975903.
12. Grabski IN, Heymach JV, Kehl KL, Kopetz S, Lau KS, Riely GJ, Schrag D, Yaeger R, Irizarry RA, Haigis KM. Effects of KRAS genetic interactions on outcomes in cancers of the lung, pancreas, and colorectum. Cancer Epidemiol Biomarkers Prev. e-Pub 2023. PMID: 37943166.
13. Zheng C, Wei Y, Zhang P, Lin K, He D, Teng H, Manyam G, Zhang Z, Liu W, Lee HRL, Tang X, He W, Islam N, Jain A, Chiu Y, Cao S, Diao Y, Meyer-Gauen S, Höök M, Malovannaya A, Li W, Hu M, Wang W, Xu H, Kopetz S, Chen Y. CRISPR-Cas9-based functional interrogation of unconventional translatome reveals human cancer dependency on cryptic non-canonical open reading frames. Nat Struct Mol Biol. e-Pub 2023. PMID: 37932451.
14. Khanduri I, Maki H, Verma A, Katkhuda R, Anandappa G, Pandurengan R, Zhang S, Mejia A, Tong Z, Soto LMS, Jadhav A, Wistuba II, Kopetz S, Parra ER, Vauthey JN, Maru DM. New Insights into Macrophage Polarization and its Prognostic Role in Patients with Colorectal Cancer Liver Metastasis. Res Sq, 2023. e-Pub 2023. PMID: 37886575.
15. Guo S, Liu X, Cheng X, Jiang Y, Ji S, Liang Q, Koval A, Li Y, Owen LA, Kim IK, Aparicio A, Shen JP, Kopetz S, Weinstein JN, DeAngelis MM, Chen R, Wang W. The DeMixSC deconvolution framework uses single-cell sequencing plus a small benchmark dataset for improved analysis of cell-type ratios in complex tissue samples. bioRxiv, 2023. e-Pub 2023. PMID: 37873318.
16. Pasquereau-Kotula E, Nigro G, Dingli F, Loew D, Poullet P, Xu Y, Kopetz S, Davis J, Peduto L, Robbe-Masselot C, Sansonetti P, Trieu-Cuot P, Dramsi S. Author Correction: Global proteomic identifies multiple cancer-related signaling pathways altered by a gut pathobiont associated with colorectal cancer. Sci Rep 13(1):17676, 2023. e-Pub 2023. PMID: 37848491.
17. Elez E, Kopetz S, Tabernero J, Bekaii-Saab T, Taieb J, Yoshino T, Manji G, Fernandez K, Abbattista A, Zhang X, Morris VK. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC. Future Oncol. e-Pub 2023. PMID: 37815847.
18. Fox DA, Bhamidipati D, Konishi T, Kaur H, You N, Raghav KPS, Ge PS, Messick C, Johnson B, Morris VK, Thomas JV, Shah P, Bednarski BK, Kopetz S, Chang GJ, Ludford K, Higbie VS, Overman MJ. Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. Eur J Cancer 194:113356. e-Pub 2023. PMID: 37827065.
19. Napolitano S, Parikh AR, Henry J, Parseghian CM, Willis J, Raghav KP, Morris VK, Johnson B, Kee BK, Dasari AN, Overman MJ, Luthra R, Drusbosky LM, Corcoran RB, Kopetz S, Sun R. Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precis Oncol 7:e2300228, 2023. PMID: 37824798.
20. Chowdhury S, Gupta R, Millstein J, Lin K, Haridas V, Zeineddine MA, Parseghian C, Lenz HJ, Kopetz S, Shen JP. Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Colorectal Cancer. JCO Precis Oncol 7:e2200422, 2023. PMID: 37487150.
21. White MG, Damania A, Alshenaifi J, Sahasrabhojane P, Peacock O, Losh J, Wong MC, Lutter-Berkova Z, Chang GJ, Futreal A, Wargo JA, Ajami NJ, Kopetz S, You YN. Young-onset Rectal Cancer: Unique Tumoral Microbiome and Correlation with Response to Neoadjuvant Therapy. Ann Surg. e-Pub 2023. PMID: 37465976.
22. Jiang L, Thall PF, Yan F, Kopetz S, Yuan Y. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials. Clin Trials:17407745231176445. e-Pub 2023. PMID: 37313712.
23. Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist. e-Pub 2023. PMID: 37311055.
24. Ghosh S, Fan F, Powell RT, Roszik J, Park Y, Stephan C, Sebastian M, Tan L, Sorokin AV, Lorenzi PL, Kopetz S, Ellis LM, Bhattacharya R. Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer. Mol Cancer Ther. e-Pub 2023. PMID: 37310170.
25. Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol 7(1):16, 2023. e-Pub 2023. PMID: 36781990.
26. Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol:JCO2201351. e-Pub 2023. PMID: 36623241.
27. Raghav K, Kopetz S, Yuan Y. Reply to Y. Yu et al. J Clin Oncol:JCO2202588. e-Pub 2023. PMID: 36595731.
28. Thatikonda V, Lu H, Jurado S, Kostyrko K, Bristow CA, Bosch K, Feng N, Gao S, Gerlach D, Gmachl M, Lieb S, Jeschko A, Machado AA, Marszalek ED, Mahendra M, Jaeger PA, Sorokin A, Strauss S, Trapani F, Kopetz S, Vellano CP, Petronczki M, Kraut N, Heffernan TP, Marszalek JR, Pearson M, Waizenegger I, Hofmann MH. Combined KRAS G12C and SOS1 inhibition enhances and extends the anti-tumor response in KRAS G12C -driven cancers by addressing intrinsic and acquired resistance. bioRxiv, 2023. e-Pub 2023. PMID: 36747713.
29. Fan F, Ghosh S, Powell R, Roszik J, Park Y, Sobieski M, Sorokin A, Stephan C, Kopetz S, Ellis LM, Bhattacharya R. Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. PLoS One 18(3):e0281063, 2023. e-Pub 2023. PMID: 36952536.
30. Parseghian C, Eluri M, Kopetz S, Raghav K. Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics. Front Cell Dev Biol 11:1176657, 2023. e-Pub 2023. PMID: 37791069.
31. Spira A, Wertheim MS, Kim EJ, Tan B, Lenz HJ, Nikolinakos P, Rich PL, Jehl G, Machl A, Ito R, Gulley JL, Kopetz S. Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial. Oncologist. e-Pub 2022. PMID: 36576431.
32. Pant S, Dragovich T, Lieu C, Jimeno A, Kundranda M, Menter D, Tchaparian E, Chen YC, Kopetz S. Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors. Invest New Drugs. e-Pub 2022. PMID: 36331676.
33. Paolucci I, Lin YM, Kawaguchi Y, Maki H, Jones AK, Calandri M, Kopetz S, Newhook TE, Brock KK, Vauthey JN, Odisio BC. Targeted exome-based predictors of patterns of progression of colorectal liver metastasis after percutaneous thermal ablation. Br J Cancer. e-Pub 2022. PMID: 36319850.
34. Parseghian CM, Sun R, Woods M, Napolitano S, Lee HM, Alshenaifi J, Willis J, Nunez S, Raghav KP, Morris VK, Shen JP, Eluri M, Sorokin A, Kanikarla P, Vilar E, Rehn M, Ang A, Troiani T, Kopetz S. Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol:JCO2201423. e-Pub 2022. PMID: 36351210.
35. Shree Bose, Barroso M, Chheda MG, Clevers H, Elez E, Kaochar S, Kopetz SE, Li XN, Meric-Bernstam F, Meyer CA, Mou H, Naegle KM, Pera MF, Perova Z, Politi KA, Raphael BJ, Robson P, Sears RC, Tabernero J, Tuveson DA, Welm AL, Welm BE, Willey CD, Salnikow K, Chuang JH, Shen X. A path to translation: How 3D patient tumor avatars enable next generation precision oncology. Cancer Cell. e-Pub 2022. PMID: 36270276.
36. Fangman B, Raghav K, Kopetz S. Circulating Tumor DNA as a Marker of Minimal Residual Disease. Oncology (Williston Park) 36(10):600-603, 2022. PMID: 36260787.
37. Sahin IH, Lin Y, Yothers G, Lucas PC, Deming D, George TJ, Kopetz S, Lieu CH, Dasari A. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US. Oncology (Williston Park) 36(10):604-608, 2022. PMID: 36260786.
38. Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open 5(10):e2236357, 2022. e-Pub 2022. PMID: 36239938.
39. Gouda MA, Duose DY, Lapin M, Zalles S, Huang HJ, Xi Y, Zheng X, Aldesoky AI, Alhanafy AM, Shehata MA, Wang J, Kopetz S, Meric-Bernstam F, Wistuba II, Luthra R, Janku F. Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures. Oncologist. e-Pub 2022. PMID: 36200910.
40. Raghav K, Ou FS, Venook AP, Innocenti F, Sun R, Lenz HJ, Kopetz S. Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance). J Clin Oncol:JCO2200365. e-Pub 2022. PMID: 36067452.
41. Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
42. Sorokin AV, Kanikarla Marie P, Bitner L, Syed M, Woods M, Manyam G, Kwong LN, Johnson B, Morris VK, Jones P, Menter DG, Lee MS, Kopetz S. Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4/6. Cancer Res. e-Pub 2022. PMID: 35913398.
43. VandenHeuvel SN, Farris HA, Noltensmeyer DA, Roy S, Donehoo DA, Kopetz S, Haricharan S, Walsh AJ, Raghavan S. Decellularized organ biomatrices facilitate quantifiable in vitro 3D cancer metastasis models. Soft Matter 18(31):5791-5806, 2022. e-Pub 2022. PMID: 35894795.
44. Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer 10(8), 2022. PMID: 36007963.
45. Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan CA, Dagogo-Jack I, Myall NJ, Richtig G, Bracht JWP, Gerlinger M, Shinozaki E, Yoshino T, Kotani D, Fangusaro JR, Gautschi O, Mazieres J, Sosman JA, Kopetz S, Subbiah V, Davies MA, Groover AL, Sullivan RJ, Flaherty KT, Johnson DB, Benedetti A, Cescon DW, Spreafico A, Zogopoulos G, Rose AAN. Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. JCO Precis Oncol 6:e2200107, 2022. PMID: 35977349.
46. Serpas Higbie V, Rogers J, Hwang H, Qiao W, Xiao L, Dasari A, Mola-Rudd K, Morris VK, Wolff RA, Raghav K, Huey R, Parseghian C, Willis J, Kopetz S, Overman MJ, Johnson B. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist. e-Pub 2022. PMID: 35946836.
47. Chun YS, Passot G, Nishioka Y, Katkhuda R, Arvide EM, Benzerdjeb N, Lopez J, Kopetz SE, Maru DM, Vauthey JN. Colorectal Liver Micrometastases: Association with RAS/TP53 Co-Mutation and Prognosis after Surgery. J Am Coll Surg 235(1):8-16, 2022. e-Pub 2022. PMID: 35703957.
48. Thein KZ, Biter AB, Banks KC, Duda AW, Saam J, Roszik J, Janku F, Skoulidis F, Heymach JV, Kopetz S, Meric-Bernstam F, Hong DS. Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer. JCO Precis Oncol 6:e2100547, 2022. PMID: 35862868.
49. Kasi PM, Fehringer G, Aleshin A, Kopetz S. Reply to F. Dayyani et al. JCO Precis Oncol 6:e2200275, 2022. PMID: 35834757.
50. Newhook TE, Overman MJ, Chun YS, Dasari A, Tzeng CD, Cao HST, Raymond V, Parseghian C, Johnson B, Nishioka Y, Kawaguchi Y, Uppal A, Vreeland TJ, Jaimovich A, Arvide EM, Cristo JV, Wei SH, Raghav KP, Morris VK, Lee JE, Kopetz S, Vauthey JN. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg. e-Pub 2022. PMID: 35797554.
51. Ryan MB, Coker O, Sorokin A, Fella K, Barnes H, Wong E, Kanikarla P, Gao F, Zhang Y, Zhou L, Kopetz S, Corcoran RB. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep 39(12):110993, 2022. PMID: 35732135.
52. Cao S, Wang JR, Ji S, Yang P, Dai Y, Guo S, Montierth MD, Shen JP, Zhao X, Chen J, Lee JJ, Guerrero PA, Spetsieris N, Engedal N, Taavitsainen S, Yu K, Livingstone J, Bhandari V, Hubert SM, Daw NC, Futreal PA, Efstathiou E, Lim B, Viale A, Zhang J, Nykter M, Czerniak BA, Brown PH, Swanton C, Msaouel P, Maitra A, Kopetz S, Campbell P, Speed TP, Boutros PC, Zhu H, Urbanucci A, Demeulemeester J, Van Loo P, Wang W. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nat Biotechnol. e-Pub 2022. PMID: 35697807.
53. Kothari A, White MG, Peacock O, Kaur H, Palmquist SM, You N, Taggart M, Salem U, Overman M, Kopetz S, Chang GJ. Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. Br J Surg 109(6):489-492, 2022. PMID: 35576377.
54. Parikh AR, Gonzalez-Gugel E, Smolyakova N, Jen MH, Toms N, Lin Y, Kim JS, Kopetz S. Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis. Oncologist 27(5):371-379, 2022. PMID: 35522557.
55. Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, Johnson B, Kopetz S, Morris V, Overman M, Parseghian C, Chang GJ, Lopez-Olivo MA, Kanwal R, Ellis LM, Dasari A. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open 5(5):e2213588, 2022. e-Pub 2022. PMID: 35608860.
56. Nishioka Y, Chun YS, Overman MJ, Cao HST, Tzeng CD, Mason MC, Kopetz SW, Bauer TW, Vauthey JN, Newhook TE, MD Anderson Cancer Center INTERCEPT Program. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg 234(4):474-483, 2022. PMID: 35290266.
57. Fakih M, Tu H, Hsu H, Aggarwal S, Chan E, Rehn M, Chia V, Kopetz S. Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer. Oncologist. e-Pub 2022. PMID: 35472176.
58. Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar JH, Luna A, Menter DG, Pilie PG, Yap TA, Kopetz S, Sander C, Korkut A. Precision combination therapies based on recurrent oncogenic co-alterations. Cancer Discov. e-Pub 2022. PMID: 35412613.
59. Kothari A, White MG, Peacock O, Kaur H, Palmquist SM, You N, Taggart M, Salem U, Overman M, Kopetz S, Chang GJ. Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. Br J Surg. e-Pub 2022. PMID: 35373260.
60. Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol 13(2):647-656, 2022. PMID: 35557581.
61. Ding S, Hsu C, Wang Z, Natesh NR, Millen R, Negrete M, Giroux N, Rivera GO, Dohlman A, Bose S, Rotstein T, Spiller K, Yeung A, Sun Z, Jiang C, Xi R, Wilkin B, Randon PM, Williamson I, Nelson DA, Delubac D, Oh S, Rupprecht G, Isaacs J, Jia J, Chen C, Shen JP, Kopetz S, McCall S, Smith A, Gjorevski N, Walz AC, Antonia S, Marrer-Berger E, Clevers H, Hsu D, Shen X. Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell. e-Pub 2022. PMID: 35508177.
62. Morris VK, Kopetz S. Don't blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic. Nat Rev Cancer. e-Pub 2022. PMID: 35277674.
63. Kasi PM, Fehringer G, Taniguchi H, Starling N, Nakamura Y, Kotani D, Powles T, Li BT, Pusztai L, Aushev VN, Kalashnikova E, Sharma S, Malhotra M, Demko ZP, Aleshin A, Rodriguez A, Billings PR, Grothey A, Taieb J, Cunningham D, Yoshino T, Kopetz S. Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO Precis Oncol 6:e2100181, 2022. PMID: 35263168.
64. Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz SE, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D. BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. J Hematol Oncol 15(1):23, 2022. e-Pub 2022. PMID: 35260176.
65. Bent A, Raghavan S, Dasari A, Kopetz S. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. Clin Colorectal Cancer. e-Pub 2022. PMID: 35450837.
66. You YN, Moskowitz J, Chang GJ, Mork M, Rodriguez-Bigas M, Bednarski BK, Messick C, Tillman M, Skibber J, Nguyen S, Kopetz S, Vilar E. Germline Cancer Risk Profiles of Young-Onset Colorectal Cancer Patients: Findings from a Prospective Universal Germline Testing and Tele-Genetics Program. Dis Colon Rectum. e-Pub 2022. PMID: 35195555.
67. Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 23(1):115-124, 2022. e-Pub 2021. PMID: 34919824.
68. Menter DG, Afshar-Kharghan V, Shen JP, Martch SL, Maitra A, Kopetz S, Honn KV, Sood AK. Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. Cancer Metastasis Rev. e-Pub 2022. PMID: 35022962.
69. Kanikarla Marie P, Sorokin AV, Bitner LA, Aden R, Lam M, Manyam G, Woods MN, Anderson A, Capasso A, Fowlkes N, Overman MJ, Menter DG, Kopetz S. Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts. Front Oncol 12:994333, 2022. e-Pub 2022. PMID: 36212401.
70. Yu IS, Kopetz S. The emergence of targetable pathways in colorectal cancer. Clin Adv Hematol Oncol 19(12):774-783, 2021. PMID: 34928933.
71. Tabernero J, Velez L, Trevino TL, Grothey A, Yaeger R, Van Cutsem E, Wasan H, Desai J, Ciardiello F, Yoshino T, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open 6(6):100328, 2021. e-Pub 2021. PMID: 34896698.
72. Wan JCM, Mughal TI, Razavi P, Dawson SJ, Moss EL, Govindan R, Tan IB, Yap YS, Robinson WA, Morris CD, Besse B, Bardelli A, Tie J, Kopetz S, Rosenfeld N. Liquid biopsies for residual disease and recurrence. Med (N Y) 2(12):1292-1313, 2021. PMID: 35590147.
73. Mu R, Xu J, Tang RS, Kopetz S, Yuan Y. A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications. Stat Med 41(2):374-389. e-Pub 2021. PMID: 34730248.
74. Nunez SK, Young CD, Griffen TL, Ohandjo AQ, McKinney LP, Kopetz S, Lillard JW. Identification of Gene Co-Expression Networks Associated with Consensus Molecular Subtype-1 of Colorectal Cancer. Cancers (Basel) 13(22), 2021. e-Pub 2021. PMID: 34830978.
75. Bhamidipati D, Verma A, Sui D, Maru D, Mathew G, Lang W, Posadas J, Hein J, Kopetz S, Futreal A, Wistuba II, Gupta S, Lee JJ, Overman MJ, Tam AL. An analysis of research biopsy core variability from over 5000 prospectively collected core samples. NPJ Precis Oncol 5(1):94, 2021. e-Pub 2021. PMID: 34707215.
76. Taku N, Yi-Qian YN, Chang GJ, Ludmir EB, Raghav KPS, Rodriguez-Bigas MA, Holliday EB, Smith GL, Minsky BD, Overman MJ, Messick C, Boyce-Fappiano D, Koong AC, Skibber JM, Koay EJ, Dasari A, Taniguchi CM, Bednarski BK, Morris VK, Kopetz S, Das P. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer 0028(21). e-Pub 2021. PMID: 34794903.
77. Lee MS, Kopetz S. Are Homologous Recombination Deficiency Mutations Relevant in Colorectal Cancer?. J Natl Cancer Inst. e-Pub 2021. PMID: 34469539.
78. Chowdhury S, Hofree M, Lin K, Maru D, Kopetz S, Shen JP. Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer. Cancers (Basel) 13(19), 2021. e-Pub 2021. PMID: 34638407.
79. Wang L, Wang E, Prado Balcazar J, Wu Z, Xiang K, Wang Y, Huang Q, Negrete M, Chen KY, Li W, Fu Y, Dohlman A, Mines R, Zhang L, Kobayashi Y, Chen T, Shi G, Shen JP, Kopetz S, Tata PR, Moreno V, Gersbach C, Crawford G, Hsu D, Huang E, Bu P, Shen X. Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF-PU.1-DPP4 Axis. Adv Sci (Weinh) 8(19):e2004673. e-Pub 2021. PMID: 34378358.
80. Kopetz S, Bent A. Going With the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays. Clin Cancer Res 27(20):5449-5451. e-Pub 2021. PMID: 34389607.
81. Kawaguchi Y, Kopetz S, Tran Cao HS, Panettieri E, De Bellis M, Nishioka Y, Hwang H, Wang X, Tzeng CD, Chun YS, Aloia TA, Hasegawa K, Guglielmi A, Giuliante F, Vauthey JN. Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status. Br J Surg 108(8):968-975. e-Pub 2021. PMID: 33829254.
82. Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol 39(4):285-294, 2021. e-Pub 2020. PMID: 33356422.
83. Chen B, Dragomir MP, Fabris L, Bayraktar R, Knutsen E, Liu X, Tang C, Li Y, Shimura T, Ivkovic TC, Cruz De Los Santos M, Anfossi S, Shimizu M, Shah MY, Ling H, Shen P, Multani AS, Pardini B, Burks JK, Katayama H, Reineke LC, Huo L, Syed M, Song S, Ferracin M, Oki E, Fromm B, Ivan C, Bhuvaneshwar K, Gusev Y, Mimori K, Menter D, Sen S, Matsuyama T, Uetake H, Vasilescu C, Kopetz S, Parker-Thornburg J, Taguchi A, Hanash SM, Girnita L, Slaby O, Goel A, Varani G, Gagea M, Li C, Ajani JA, Calin GA. The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology 159(6):2146-2162.e33, 2020. e-Pub 2020. PMID: 32805281.
84. Kopetz S. Circulating tumor DNA as a marker of minimal residual disease in colorectal cancer. Clin Adv Hematol Oncol 18(12):791-792, 2020. PMID: 33406055.
85. Johnson B, Kopetz S. Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer. Target Oncol 15(5):567-577, 2020. e-Pub 2020. PMID: 32889679.
86. Advani SM, Swartz MD, Loree J, Davis JS, Sarsashek AM, Lam M, Lee MS, Bressler J, Lopez DS, Daniel CR, Morris V, Shureqi I, Kee B, Dasari A, Vilar E, Overman M, Hamilton S, Maru D, Braithwaite D, Kopetz S. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer 20(2):137-147. e-Pub 2020. PMID: 33229221.
87. Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, Pan BF, Lorenzi PL, Hurd M, Mittendorf EA, Peterson CB, Javle M, Bristow C, Kim M, Tuveson DA, Hawke D, Kopetz S, Wolff RA, Hwu P, Maitra A, Roszik J, Yee C, Lizée G. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun 11(1):5332, 2020. e-Pub 2020. PMID: 33087697.
88. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. e-Pub 2020. PMID: 32632268.
89. Jácome AA, Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman M, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng C. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. e-Pub 2020. PMID: 32665092.
90. Lin SH, Raju GS, Huff C, Ye Y, Gu J, Chen JS, Hildebrandt MAT, Liang H, Menter DG, Morris J, Hawk E, Stroehlein JR, Futreal A, Kopetz S, Mishra L, Wu X. The somatic mutation landscape of premalignant colorectal adenoma. Gut 67(7):1299-1305, 2018. e-Pub 2017. PMID: 28607096.
91. Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 23(15):4146-4154, 2017. e-Pub 2017. PMID: 28280091.
92. Leung ML, Davis A, Gao R, Casasent A, Wang Y, Sei E, Vilar E, Maru D, Kopetz S, Navin NE. Single-cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancer. Genome Res 27(8):1287-1299, 2017. e-Pub 2017. PMID: 28546418.
93. Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res 23(14):3657-3666, 2017. e-Pub 2017. PMID: 28096270.
94. Mehrotra M, Singh RR, Chen W, Huang RSP, Almohammedsalim AA, Barkoh BA, Simien CM, Hernandez M, Behrens C, Patel KP, Routbort MJ, Broaddus RR, Medeiros LJ, Wistuba II, Kopetz S, Luthra R. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn 19(4):514-524, 2017. e-Pub 2017. PMID: 28506684.
95. Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev. e-Pub 2017. PMID: 28730545.
96. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. e-Pub 2017. PMID: 28734759.
97. Lam M, Roszik J, Kanikarla-Marie P, Davis JS, Morris J, Kopetz S, Menter DG. The potential role of platelets in the consensus molecular subtypes of colorectal cancer. Cancer Metastasis Rev. e-Pub 2017. PMID: 28681242.
98. Kumar R, Herold JL, Schady D, Davis J, Kopetz S, Martinez-Moczygemba M, Murray BE, Han F, Li Y, Callaway E, Chapkin RS, Dashwood WM, Dashwood RH, Berry T, Mackenzie C, Xu Y. Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. PLoS Pathog 13(7):e1006440, 2017. e-Pub 2017. PMID: 28704539.
99. Park IJ, You YN, Skibber JM, Rodriguez-Bigas MA, Das P, Eng C, Kopetz S, Wolff RA, Crane CH, Krishnan S, Minsky B, Hu CY, Nguyen S, Chang GJ. Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol 40(3):277-282, 2017. e-Pub 2016. PMID: 27028350.
100. Yamashita S, Odisio BC, Huang SY, Kopetz SE, Ahrar K, Chun YS, Conrad C, Aloia TA, Gupta S, Harmoush S, Hicks ME, Vauthey JN. Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases. Eur J Surg Oncol 43(6):1040-1049, 2017. e-Pub 2017. PMID: 28187878.
101. Arango NP, Brusco L, Mills Shaw KR, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget 8(26):41806-41814, 2017. e-Pub 2017. PMID: 28415679.
102. Sundar R, Hong DS, Kopetz S, Yap TA. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discov 7(6):558-560, 2017. PMID: 28576843.
103. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. PMID: 28424412.
104. Long Y, Sanchez-Espiridion B, Lin M, White L, Mishra L, Raju GS, Kopetz S, Eng C, Hildebrandt MAT, Chang DW, Ye Y, Liang D, Wu X. Global and targeted serum metabolic profiling of colorectal cancer progression. Cancer. e-Pub 2017. PMID: 28640361.
105. Ikoma N, You YN, Bednarski BK, Rodriguez-Bigas MA, Eng C, Das P, Kopetz S, Messick C, Skibber JM, Chang GJ. Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. J Clin Oncol:JCO2016721464. e-Pub 2017. PMID: 28657814.
106. Kanikarla-Marie P, Lam M, Menter DG, Kopetz S. Platelets, circulating tumor cells, and the circulome. Cancer Metastasis Rev. e-Pub 2017. PMID: 28667367.
107. Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer 123(6):1011-1017, 2017. e-Pub 2016. PMID: 27859010.
108. Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Bryan Rumble R, Temple-Smolkin R, B Ventura C, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med 141(5):625-657, 2017. e-Pub 2017. PMID: 28165284.
109. Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35(13):JCO2016719807, 2017. e-Pub 2017. PMID: 28165299.
110. Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Oncol Pract 13(5):JOP2017022152, 2017. e-Pub 2017. PMID: 28350513.
111. Janku F, Zhang S, Waters J, Liu L, Huang H, Subbiah V, Hong DS, Karp D, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DD, Zhao Y, Javle M, Kopetz S, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach J, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer. Clin Cancer Res. e-Pub 2017. PMID: 28536309.
112. Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, Shimizu M, Redis RS, Shah MY, Zhang X, Okugawa Y, Jung EJ, Tsirigos A, Huang L, Ferdin J, Gafà R, Spizzo R, Nicoloso MS, Paranjape AN, Shariati M, Tiron A, Yeh JJ, Teruel-Montoya R, Xiao L, Melo SA, Menter D, Jiang ZQ, Flores ER, Negrini M, Goel A, Bar-Eli M, Mani SA, Liu CG, Lopez-Berestein G, Berindan-Neagoe I, Esteller M, Kopetz S, Lanza G, Calin GA. N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biol 18(1):98, 2017. e-Pub 2017. PMID: 28535802.
113. Goldstein JB, Wu W, Borras E, Masand G, Cuddy A, Mork ME, Bannon SA, Lynch PM, Rodriguez-Bigas M, Taggart MW, Wu J, Scheet P, Kopetz S, You YN, Vilar E. Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?. Clin Cancer Res. e-Pub 2017. PMID: 28522602.
114. Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol:JCO2016714394. e-Pub 2017. PMID: 28486044.
115. Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S. Modeling of Patient Derived Xenografts in Colorectal Cancer. Mol Cancer Ther. e-Pub 2017. PMID: 28468778.
116. Odisio BC, Yamashita S, Huang SY, Harmoush S, Kopetz SE, Ahrar K, Shin Chun Y, Conrad C, Aloia TA, Gupta S, Hicks ME, Vauthey JN. Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg 104(6):760-768, 2017. e-Pub 2017. PMID: 28240361.
117. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight 2(8). e-Pub 2017. PMID: 28422758.
118. Sarshekeh AM, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(3):e0173345, 2017. e-Pub 2017. PMID: 28267766.
119. Khan M, Korphaisarn K, Saif A, Foo WC, Kopetz S. Early-Onset Signet-Ring Cell Adenocarcinoma of the Colon: A Case Report and Review of the Literature. Case Rep Oncol Med 2017:2832180, 2017. e-Pub 2017. PMID: 28326211.
120. Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, Tan AC, Zheng X, Zhang Q, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt G, Messersmith WA. A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. Int J Cancer 138(1):195-205, 2016. e-Pub 2015. PMID: 26152787.
121. Lee MS, Kopetz S. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer. Clin Colorectal Cancer 14(4):203-18, 2015. e-Pub 2015. PMID: 26077270.
122. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. The Consensus Molecular Subtypes of Colorectal Cancer. Nat Med 21(11):1350-6, 2015. e-Pub 2015. PMID: 26457759.
123. Shah MS, Fogelman DR, Raghav KP, Heymach JV, Tran HT, Jiang ZQ, Kopetz S, Daniel CR. Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. Cancer 121(17):2968-75, 2015. e-Pub 2015. PMID: 25975416.
124. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol 33(25):2753-62, 2015. e-Pub 2015. PMID: 26014291.
125. Chang GJ, Kopetz S. Coordination of care in colon cancer. Cancer 121(18):3201-2, 2015. e-Pub 2015. PMID: 26043269.
126. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition with Dabrafenib and Trametinib in BRAF V600 Mutant Colorectal Cancer. J Clin Oncol. e-Pub 2015. PMID: 26392102.
127. Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat Rev 41(8):653-9, 2015. e-Pub 2015. PMID: 26220150.
128. Brudvik KW, Kopetz ES, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 102(10):1175-83, 2015. e-Pub 2015. PMID: 26206254.
129. Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, Fogelman D, Shureiqi I, Jacobs C, Malik Z, Jimenez CA, Wolff RA, Abbruzzese JL, Gallick G, Eng C. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs 33(4):977-84, 2015. e-Pub 2015. PMID: 26062928.
130. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 107(7), 2015. e-Pub 2015. PMID: 25863335.
131. Chen T, Sun Y, Ji P, Kopetz S, Zhang W. Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene 34(31):4019-31, 2015. e-Pub 2014. PMID: 25328138.
132. Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz ES, Subbiah V, Alvarez RH, Davies MA, Jabbar KJ, Roy-Chowdhuri S, Lazar AJ, Medeiros LJ, Broaddus RR, Luthra R, Routbort MJ. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res 21(11):2644-51, 2015. e-Pub 2015. PMID: 25695693.
133. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(14):12809-21, 2015. e-Pub 2015. PMID: 25980577.
134. Mise Y, Kopetz S, Mehran RJ, Aloia TA, Conrad C, Brudvik KW, Taggart MW, Vauthey JN. Is Complete Liver Resection Without Resection of Synchronous Lung Metastases Justified?. Ann Surg Oncol 22(5):1585-92, 2015. e-Pub 2014. PMID: 25373535.
135. Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731-6, 2015. e-Pub 2015. PMID: 25628445.
136. Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock MD, Braicu C, Pileczki V, Vincent K, Pichler M, Stiegelbauer V, Hoefler G, Almeida MI, Hsiao A, Zhang X, Primrose JN, Packham GK, Liu K, Bojja K, Gafà R, Xiao L, Rossi S, Song JH, Vannini I, Fanini F, Kopetz S, Zweidler-McKay P, Wang X, Ionescu C, Irimie A, Fabbri M, Lanza G, Hamilton SR, Berindan-Neagoe I, Medico E, Mirnezami AH, Calin GA, Nicoloso MS. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut. e-Pub 2015. PMID: 25804630.
137. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112(6):1088-97, 2015. e-Pub 2015. PMID: 25688736.
138. Bresalier RS, Kopetz S, Brenner DE. Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test?. Dig Dis Sci 60(3):664-71, 2015. e-Pub 2015. PMID: 25680874.
139. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clin Chem 61(3):544-53, 2015. e-Pub 2015. PMID: 25626406.
140. Atreya CE, Corcoran RB, Kopetz S. Expanded RAS: Refining the Patient Population. J Clin Oncol 33(7):682-5, 2015. e-Pub 2015. PMID: 25584005.
141. Mise Y, Zimmitti G, Shindoh J, Kopetz S, Loyer EM, Andreou A, Cooper AB, Kaur H, Aloia TA, Maru DM, Vauthey JN. RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of Colorectal Liver Metastases. Ann Surg Oncol 22(3):834-42, 2015. e-Pub 2014. PMID: 25227306.
142. Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res 21(4):899-906, 2015. e-Pub 2014. PMID: 25516888.
143. Fan F, Bellister S, Lu J, Ye X, Boulbes DR, Tozzi F, Sceusi E, Kopetz S, Tian F, Xia L, Zhou Y, Bhattacharya R, Ellis LM. The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells. Br J Cancer 112(3):539-46, 2015. e-Pub 2014. PMID: 25535733.
144. Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, Maru D, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 112(3):424-8, 2015. e-Pub 2014. PMID: 25535726.
145. Kopetz S, Tabernero J, Rosenberg R, Jiang ZQ, Moreno V, Bachleitner-Hofmann T, Lanza G, Stork-Sloots L, Maru D, Simon I, Capellà G, Salazar R. Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors. Oncologist 20(2):127-33, 2015. e-Pub 2015. PMID: 25561511.
146. Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S, Falchook G. BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity. Horm Cancer 6(1):21-36, 2015. e-Pub 2014. PMID: 25467940.
147. Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS, Jang HJ, Park YY, Kopetz S, Kim SS, Oh SC, Lee JS. Significant Association of oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients. Clin Cancer Res 21(2):357-64, 2015. e-Pub 2014. PMID: 25388162.
148. San Lucas FA, Fowler J, Chang K, Kopetz S, Vilar E, Scheet P. Cancer in silico Drug Discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes. Mol Cancer Ther 13(12):3230-40, 2014. e-Pub 2014. PMID: 25349306.
149. Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK. Therapeutic Silencing of KRAS using Systemically Delivered siRNAs. Mol Cancer Ther 13(12):2876-85, 2014. e-Pub 2014. PMID: 25281617.
150. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, Kim SB, Kopetz S, Ledoux AA, Gopal YN, Pereira CG, Deng W, Lee JS, Nathanson KL, Aldape KD, Prieto VG, Stuart D, Davies MA. Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. Clin Cancer Res 20(21):5537-46, 2014. e-Pub 2014. PMID: 24803579.
151. Zhou JH, Rosen D, Andreou A, Brouquet A, Abbott D, Loyer E, Gonzalez-Angulo AM, Kopetz S, Meric-Bernstam F, Kuerer H, Abdalla E, Vauthey JN, Sahin AA, Maru DM. Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Ann Diagn Pathol 18(5):266-70, 2014. e-Pub 2014. PMID: 25205085.
152. Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood AK, Hawk ET. Convergence of nanotechnology and cancer prevention: are we there yet?. Cancer Prev Res (Phila) 7(10):973-92, 2014. e-Pub 2014. PMID: 25060262.
153. Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic Characteristics and Gene Expression Analyses of Non-KRAS 12/13, RAS-Mutated Metastatic Colorectal Cancer. Ann Oncol 25(10):2008-14, 2014. e-Pub 2014. PMID: 25009008.
154. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 13(3):164-71, 2014. e-Pub 2014. PMID: 25069797.
155. Aloia TA, Zimmitti G, Conrad C, Gottumukalla V, Kopetz S, Vauthey JN. Return to intended oncologic treatment (RIOT): A novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol 110(2):107-14, 2014. e-Pub 2014. PMID: 24846705.
156. Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman MJ. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 25(5):1032-8, 2014. e-Pub 2014. PMID: 24585723.
157. Haynes AB, You YN, Hu CY, Eng C, Kopetz ES, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Chang GJ. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer 120(8):1162-70, 2014. e-Pub 2014. PMID: 24474245.
158. Gong J, Xie J, Bedolla R, Rivas P, Chakravarthy D, Freeman JW, Reddick R, Kopetz S, Peterson A, Wang H, Fischer SM, Kumar AP. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer. Clin Cancer Res 20(5):1259-73, 2014. e-Pub 2014. PMID: 24520096.
159. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev 33(1):231-69, 2014. e-Pub 2014. PMID: 24696047.
160. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH. Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase 1 Trial. Int J Radiat Oncol Biol Phys 88(2):301-5, 2014. e-Pub 2013. PMID: 24315563.
161. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pagès F. Towards the introduction of the Immunoscore in the classification of malignant tumors. J Pathol 232(2):199-209, 2014. e-Pub 2013. PMID: 24122236.
162. Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G, Izzo J, He N, Wei C, Baladandayuthapani V, Liang H, Kopetz S, Powis G, Guo GL. FXR Silencing in Human Colon Cancer by DNA methylation and KRAS Signaling. Am J Physiol Gastrointest Liver Physiol 306(1):G48-58, 2014. e-Pub 2013. PMID: 24177031.
163. Kopetz S, Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru D, Elvin P, Gallick G. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer 14:660, 2014. e-Pub 2014. PMID: 25208577.
164. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations. Mol Cancer Ther 12(12):2857-63, 2013. e-Pub 2013. PMID: 24092809.
165. Vauthey JN, Kopetz SE . From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS. Cancer 119(23):4083-5, 2013. e-Pub 2013. PMID: 24105015.
166. Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, You YN, Das P, Krishnan S, Crane CH, Rodriguez-Bigas M, Skibber J, Ellis L, Eng C, Kopetz S, Maru DM. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer 119(24):4231-41, 2013. e-Pub 2013. PMID: 24089344.
167. Morris V, Kopetz S. Clinical biomarkers in colorectal cancer. Clin Adv Hematol Oncol 11(12):768-76, 2013. PMID: 24893280.
168. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, Curley SA, Aloia TA, Maru DM. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 258(4):619-26; discussion 626-7, 2013. PMID: 24018645.
169. Jiang ZQ, Varadhachary G, Wang X, Kopetz S, Lee JE, Wang H, Shroff R, Katz M, Wolff RA, Fleming J, Overman MJ. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol 24(9):2349-53, 2013. e-Pub 2013. PMID: 23704197.
170. Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafà R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia-Manero G, Patijn GA, Gotley DC, Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K, Taniguchi I, Song MA, Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K, Mori M, Sieuwerts AM, Martens JW, Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopetz S, Fodde R, Calin GA. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res 23(9):1446-61, 2013. e-Pub 2013. PMID: 23796952.
171. Andreou A, Aloia TA, Brouquet A, Dickson PV, Zimmitti G, Maru DM, Kopetz S, Loyer EM, Curley SA, Abdalla EK, Vauthey JN. Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy. Ann Surg 257(6):1079-88, 2013. e-Pub 2013. PMID: 23426338.
172. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with P13K inhibition or demethylating agents. Clin Cancer Res 19(3):657-667, 2013. e-Pub 2012. PMID: 23251002.
173. Clary BM, Grothey A, Kopetz S, Marsh RD. Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. HPB (Oxford) 15(2):116-8, 2013. PMID: 23297722.
174. Overman MJ, Modak J, Kopetz ES, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL. Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?. J Clin Oncol 31(1):17-22, 2013. e-Pub 2012. PMID: 23129736.
175. Morris V, Kopetz S. BRAF inhibitors in clinical oncology. F1000Prime Rep 5:11, 2013. e-Pub 2013. PMID: 23585929.
176. Park YY, Lee SS, Lim JY, Kim SC, Kim SB, Sohn BH, Chu IS, Oh SC, Park ES, Jeong W, Kim SS, Kopetz S, Lee JS. Comparison of prognostic genomic predictors in colorectal cancer. PLoS One 8(4):e60778, 2013. e-Pub 2013. PMID: 23626670.
177. Kopetz S. "Right drug for the right patient". Am Soc Clin Oncol Educ Book 2013:115-20, 2013. PMID: 23714474.
178. Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One 8(10):e77117, 2013. e-Pub 2013. PMID: 24143206.
179. Park YY, Lee SS, Lim JY, Kim SC, Kim SB, Sohn BH, Chu IS, Oh SC, Park ES, Jeong W, Kim SS, Kopetz S, Lee JS. Correction: Comparison of Prognostic Genomic Predictors in Colorectal Cancer. PLoS One 8(12), 2013. e-Pub 2013. PMID: 24358104.
180. Conte B, Kopetz S. Challenges and strategies for identifying biomarkers for colorectal cancer. Colorectal Cancer 2(6):487-489, 2013. PMID: 25598846.
181. Overman MJ, Zhang J, Kopetz S, Davies M, Zhi-Qin J, Stemke-Hale K, Rümmele P, Pilarsky C, Grützmann R, Hamilton S, Hwang R, Abbruzzese JL, Varadhachary G, Broom B, Wang H. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One 8(6):e65144, 2013. e-Pub 2013. PMID: 23776447.
182. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz ES, Win S, Kurzrock R. Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: the MD Anderson Cancer Center Experience. Clin Colorectal Cancer 11(4):297-303, 2012. e-Pub 2012. PMID: 22537607.
183. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases. J Clin Oncol 30(36):4566-72, 2012. e-Pub 2012. PMID: 23150701.
184. Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN. Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases. Ann Surg 256(4):642-50, 2012. e-Pub 2012. PMID: 22968062.
185. Vauthey JN, Kopetz S, Aloia TA, Andreou A. KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary. Br J Cancer 107(8):1442-3, 2012. e-Pub 2012. PMID: 23018559.
186. Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB, Kim J, Kim SC, Chu IS, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee JS. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 61(9):1291-8, 2012. e-Pub 2011. PMID: 21997556.
187. Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C. Survival Benefit Associated With Surgical Oophorectomy in Patients With Colorectal Cancer Metastatic to the Ovary. Clin Colorectal Cancer 11(3):191-4, 2012. e-Pub 2012. PMID: 22280844.
188. Dai J, Gu J, Huang M, Eng C, Kopetz ES, Ellis LM, Hawk E, Wu X. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis 33(7):1327-31, 2012. e-Pub 2012. PMID: 22505654.
189. Overman MJ, Hu CY, Kopetz ES, Abbruzzese JL, Wolff RA, Chang GJ. A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease. Ann Surg Oncol 19(5):1439-45, 2012. e-Pub 2011. PMID: 22187121.
190. Ferrarotto R, Machado K, Mak MP, Shah N, Takahashi TK, Costa FP, Overman MJ, Kopetz S, Hoff PM. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer 48(6):820-6, 2012. e-Pub 2012. PMID: 22330318.
191. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 72(3):779-89, 2012. e-Pub 2011. PMID: 22180495.
192. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10(1):205, 2012. e-Pub 2012. PMID: 23034130.
193. Boonsirikamchai P, Asran MA, Maru DM, Vauthey JN, Kaur H, Kopetz ES, Loyer EM. CT Findings of Response and Recurrence, Independent of Change in Tumor Size, in Colorectal Liver Metastasis Treated With Bevacizumab. AJR Am J Roentgenol 197(6):W1060-6, 2011. PMID: 22109320.
194. Angelo LS, Wu JY, Meng F, Sun M, Kopetz S, McCutcheon IE, Slopis JM, Kurzrock R. Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. Mol Cancer Ther 10(11):2094-103, 2011. e-Pub 2011. PMID: 21903608.
195. Brouquet A, Overman MJ, Kopetz ES, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. Cancer 117(19):4484-92, 2011. e-Pub 2011. PMID: 21446046.
196. Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis. Clin Cancer Res 17(19):6130-9, 2011. e-Pub 2011. PMID: 21953501.
197. Ferrarotto R, Pathak P, Maru D, Agarwal A, Overman M, Hoff PM, Kopetz ES. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 10(3):178-82, 2011. e-Pub 2011. PMID: 21855039.
198. George B, Kopetz ES. Predictive and Prognostic Markers in Colorectal Cancer. (Invited). Curr Oncol Rep 13(3):206-15, 2011. e-Pub 2011. PMID: 21373987.
199. Fogelman DR, Wolff RA, Kopetz ES, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL. Evidence for the Efficacy of Iniparib, a PARP-1 Inhibitor, in BRCA2-associated Pancreatic Cancer. Anticancer Res 31(4):1417-20, 2011. PMID: 21508395.
200. Brouquet A, Abdalla EK, Kopetz ES, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29(8):1083-90, 2011. e-Pub 2011. PMID: 21263087.
201. Tran B, Kopetz ES, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. e-Pub 2011. PMID: 21456008.
202. Ihle NT, Powis G, Kopetz ES. PI-3-Kinase Inhibitors in Colorectal Cancer (Peer-reviewed Review). Curr Cancer Drug Targets 11(2):190-8, 2011. e-Pub 2010. PMID: 21158718.
203. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz ES, McConkey DJ, Evans DB, Gallick GE. ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma. PLoS One 6(6):e20636, 2011. e-Pub 2011. PMID: 21695188.
204. Silberfein EJ, Kattepogu KM, Hu CY, Skibber JM, Rodriguez-Bigas MA, Feig B, Das P, Krishnan S, Crane C, Kopetz S, Eng C, Chang GJ. Long-term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer. Ann Surg Oncol 17(11):2863-9, 2010. e-Pub 2010. PMID: 20552409.
205. Maru DM, Kopetz S, Boonsirikamchai P, Agarwal A, Chun YS, Wang H, Abdalla EK, Kaur H, Charnsangavej C, Vauthey JN, Loyer EM. Tumor Thickness at the Tumor-normal Interface: A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases. Am J Surg Pathol 34(9):1287-1294, 2010. e-Pub 2010. PMID: 20697255.
206. Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, Kopetz S, Garrett C, Curley SA, Abdalla EK. Surgical Strategies for Synchronous Colorectal Liver Metastases in 156 Consecutive Patients: Classic, Combined or Reverse Strategy?. J Am Coll Surg 210(6):934-41, 2010. PMID: 20510802.
207. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, Curley SA, Abdalla EK, Capussotti L, Vauthey JN. Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases. Ann Surg Oncol 17(11):2870-6. e-Pub 2010. PMID: 20567921.
208. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 49(4):474-9, 2010. PMID: 20397775.
209. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA, Kopetz S. Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury. J Clin Oncol 28(15):2549-2555, 2010. e-Pub 2010. PMID: 20406923.
210. Lieu C, Kopetz S. The SRC family of protein tyrosine kinases: A new and promising target for colorectal cancer therapy. (Peer-reviewed Review). Clin Colorectal Cancer 9(2):89-94, 2010. PMID: 20378502.
211. Vauthey JN, Nordlinger B, Kopetz S, Poston G. Sequenced Chemotherapy and Surgery for Potentially Resectable Colorectal Liver Metastases: A Debate Over Goals of Research and an Approach While the Jury Remains Out. Ann Surg Oncol 17(8):1983-1986, 2010. PMID: 20232164.
212. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102(1):144-50, 2010. e-Pub 2009. PMID: 19935793.
213. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. J Clin Oncol 28(3):453-9, 2010. e-Pub 2009. PMID: 20008624.
214. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Charnsangavej C, Loyer EM. Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases. JAMA 302(21):2338-2344, 2009. PMID: 19952320.
215. Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, Kopetz S. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 8(4):225-30, 2009. PMID: 19822514.
216. Kopetz S, Chang G, Overman M, Eng C, Larson DW, Grothey A, Vauthey JN, Sargent D, McWilliams R. Improved Survival in Metastatic Colorectal Cancer is Associated with Sequential Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 27(22):3677-83, 2009. e-Pub 2009. PMID: 19470929.
217. Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Delclos ME, Krishnan S, Crane CH, Das P.. Sacral Insufficiency Fractures After Preoperative Chemoradiation for Rectal Cancer: Incidence, Risk Factors, and Clinical Course. Int J Radiat Oncol Biol Phys 74(3):818-23, 2009. e-Pub 2009. PMID: 19147305.
218. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 26(15S):4538, 2009. e-Pub 2009. PMID: 19164203.
219. Rossi S, Kopetz S, Davuluri R, Hamilton SR, Calin GA. MicroRNAs, ultraconserved genes and colorectal cancers. (Invited). Int J Biochem Cell Biol 42(8):1291-1297, 2009. e-Pub 2009. PMID: 19497386.
220. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE.. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9):3842-9, 2009. e-Pub 2009. PMID: 19383922.
221. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16(3):614-22, 2009. e-Pub 2009. PMID: 19130139.
222. Chang DZ, Kumar V, Ma Y, Li K, Kopetz S. Individualized Therapies in Colorectal Cancer: KRAS as a Marker for Response to EGFR-targeted Therapy (Invited Editorial). J Hematol Oncol 2(18):18, 2009. e-Pub 2009. PMID: 19386128.
223. Kim MP, Park SI, Kopetz S, Gallick GE.. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res 1(335):249-59, 2009. e-Pub 2008. PMID: 18815812.
224. Fogelman DR, Kopetz S, Eng C.. Emerging Drugs for Colorectal Cancer (Invited). Expert Opin Emerg Drugs 13(4):629-42, 2008. PMID: 19046131.
225. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW.. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26(32):5254-60, 2008. e-Pub 2008. PMID: 18854565.
226. Blazer DG, Kish U, Maru DM, Kopetz S, Overman M, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover K, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point after Resection of Hepatic Colorectal Metastases. J Clin Oncol 59(33):5344-51, 2008. e-Pub 2008. PMID: 18936472.
227. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 113(8):2038-45, 2008. e-Pub 2008. PMID: 18759326.
228. Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL.. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26(8):794-9, 2008. PMID: 18798063.
229. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbrizzese JL.. Phase I study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest. New Drugs 26(5), 2008. e-Pub 2008. PMID: 18528634.
230. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA.. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer 7(5):338-42, 2008. PMID: 18794067.
231. Hoff PM, Kopetz S, Thomas MB, Langleben A, Rinaldi D, Anthony L, Wolff RA, Lassere Y, Abbruzzese JL. A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer 99(5):722-6, 2008. e-Pub 2008. PMID: 18728662.
232. Kauffman CR, Mahvash A, Kopetz S, Wolff RA, Ensor J, Wallace MJ. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. Cancer 14(10):2283-8, 2008. PMID: 18344210.
233. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway. J Clin Oncol 26(12):2000-5, 2008. PMID: 18421052.
234. Dhillon N, Kopetz S, Pei BL, Fabbro ED, Zhang T, Bruera E. Clinical findings of a palliative care consultation team at a comprehensive cancer center. J Palliat Med 11(2):191-7, 2008. PMID: 18333733.
235. Kopetz S, Freitas D, Calabrichi A, Hoff PM. Adjuvant Chemotherapy for Stage II Colon Cancer (Peer-Reviewed Review). Oncology 22(3):260-70, 2008. PMID: 18494354.
236. Politano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz S. Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness. Clin Colorectal Cancer 1(1):55-9, 2008. PMID: 18279578.
237. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. J Gastrointest Surg 11(11):1498-1505, 2007. e-Pub 2007. PMID: 17849166.
238. Kopetz S, Jimenez C, Tu SM, Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. Eur Respir J 29(4):813-5, 2006. PMID: 17400880.
239. Kopetz S. Endothelin-1 as a Target For Therapeutic Intervention in Prostate Cancer (Invited). Invest New Drugs 20:173-82, 2002. PMID: 12099577.
240. Kopetz ES, TH Magnuson, MD Duncan, JS Bender, KD Lillemoe, TA Gordon, JL Cameron, JW Harmon. Complications of neglected cholelithiasis account for significant surgical mortality in the elderly. Surg Forum(52):489-91, 2000.
241. Kopetz S, Steele CD, Brandt J, Baker A, Kronberg M, Galik E, Steinberg M, Warren A, Lyketsos CG. Characteristics and outcomes of dementia residents in an assisted living facility. Int J Geriatr Psychiatry 15(7):586-93, 2000. PMID: 10918338.
242. Cheng MD, Nash TM, Kopetz ES. Retrieval of Aerosol Optical Thickness by Means of the Least-Median-Squares Robust Algorithm. Journal of Aerosol Science 30:805-17, 1999.
243. Walczak WJ, Xiao JM, Kopetz ES, Lease K, Grau H, Lee SP, Han MK, and Knutson JR. Golden Ruler: Very Long-Range Resonance Energy Transfer to Surface Plasmon Acceptors. Biophysical Journal, 72:367, 1997.

Invited Articles

1. Kopetz S. Novel Targets for Systemic Therapy of Colorectal Cancer. Clin Adv Hematol Oncol 6(1):38-40, 2008. PMID: 18322439.
2. Kopetz S, Shah AN, Gallick GE. SRC continues aging: current and future clinical directions. Clin Cancer Res 13(24):7232-6, 2007. PMID: 18094400.
3. Kopetz S. Targeting Src and Epidermal Growth Factor Receptor in Colorectal Cancer: Rationale and Progress Into the Clinic. Gastrointestinal Cancer Research 1:S37-41, 2007.
4. Kopetz S, Hoff PM. Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in management. Oncology (Williston Park) 19(13 Suppl 6):11-7, 2005. PMID: 16502665.
5. Kopetz S, Kim ES. Adjuvant Chemotherapy in Non-Small Cell Lung Cancer. American Journal of Oncology Review (Pulmonary Supplement):1-4, 2005.

Manuals, Teaching Aids, Other Teaching Publications

1. Kopetz ES. Etiology and Management of Bowel Perforation in Patients with Colorectal Cancer” Gastrointestinal Malignancies: Putting Theory Into Practice at M. D. Anderson. M. D. Anderson: Houston, Texas, 2007.

Editorials

1. Villarreal OE, Kopetz S. EMP1+ tumor cells drive metastatic relapse. Cell Res. PMID: 36646758.
2. Eluri M, Kopetz S, Parseghian CM. Truncal dynamics may trump: serial ctDNA to predict early therapeutic response. Clin Cancer Res. PMID: 36378102.
3. Fedirko V, Kopetz S, Daniel CR. Diverticular disease and cancer risk: More than a gut feeling. J Natl Cancer Inst. PMID: 36200895.
4. Davies MA, Kopetz S. Overcoming resistance to MAPK pathway inhibitors. J Natl Cancer Inst 105(1):9-10, 2013. PMID: 23250957.
5. Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res 18(19):5160-2, 2012. PMID: 22912394.
6. Morelli MP, Kopetz S. Hurdles and complexities of codon 13 KRAS mutations. J Clin Oncol 30(29):3565-7, 2012. PMID: 22927534.
7. Kopetz S, Abbruzzese J. Barriers to Integrating Gene Profiling for Stage II Colon Cancer. Clinical Cancer Research 15(24), 2009. PMID: 19996205.
8. Eng C, Kopetz S. Commentary: Practice Patterns and Potential Impact on Quality Measurements for a Practicing Physician. Journal of Oncology Practice 5(5):233-5, 2009.
9. Overman M, Kopetz S. Picking the Right Road for Metastatic Colorectal Cancer Patients. Oncology 22(13):1482-3, 2008. PMID: 19227576.
10. Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet 371(9617):963-5, 2008. PMID: 18358910.

Abstracts

1. Scott Kopetz, Eric Van Cutsem, Yasutoshi Kuboki, Benny Johnson, Tetsuya Katakabe, Min He, Shorena Archuadze, Lin Shen. A phase Ia/Ib, open-label, dose escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy (CT) in patients (pts) with advanced GI cancers. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
2. Scott Kopetz, Stefan Kasper, Fernando Rivera, Christophe Tournigand, Yuan Cheng, Priya Deshpande, Denise D'Alessio, Nabil Amirouchene Angelozzi, Ana Bento Pereira da Silva, Neil Howard Segal. Patient-reported outcomes (PROs) and biomarker assessments in daNIS-3, a phase II platform study of NIS793 (anti–TGF-β monoclonal antibody) and other investigational drug combinations with standard of care (SOC) vs SOC alone in patients (pts) with second-line metastatic colorectal cancer (mCRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
3. Scott Kopetz, Takayuki Yoshino, Tae Won Kim, Rona Yaeger, Jayesh Desai, Harpreet Singh Wasan, Eric Van Cutsem, Tim Maughan, Cathy Eng, Jeanne Tie, Elena Elez, Sara Lonardi, Xiaosong Zhang, Chin-Hee Chung, Tiziana Usari, Tim Nicholz, Danielle A. Murphy, Josep Tabernero, Fortunato Ciardiello. BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
4. Shengli Ding, Preeti Kanikarla Marie, Ray Zhang, Nicholas Baro, Daniel W Brown, Alan Bohn, Kelly Pittman, Marcin Paduch, Shiaowen David Hsu, Scott Kopetz, Xiling Shen. Identifying targeted therapy combination for refractory colorectal cancer using micro-organospheres. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
5. Anwaar Saeed, Reagan Barnett, Emil Lou, Luciana Madeira da Silva, May Thet Cho, Christopher Hanyoung Lieu, Marwan Fakih, Scott Kopetz, Jonathan M. Loree, Sepideh Gholami. A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
6. Van K. Morris, Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal, Patrick M Boland, Dustin A. Deming, Aaron James Scott, Howard John Lim, Theodore S. Hong, Norman Wolmark, Thomas J. George. Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
7. Allison Janak, Oliver Peacock, Michael White, Montserrat Guraieb-Trueba, Sa Thi Nguyen, Jumanah Alshenaifi, Scott Kopetz, Benny Johnson, Grace L. Smith, George J. Chang, Y. Nancy You. Internet-based assessment tools for predicting colorectal cancer risk: How do they communicate individualized risk to the young adult?. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
8. Van K. Morris, Katherine A Guthrie, Scott Kopetz, Rimini Breakstone, Thomas Benjamin Karasic, Zishuo Ian Hu, Shay Bellasea, Marwan Fakih, Sepideh Gholami, Philip Jordan Gold, Philip Agop Philip. Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
9. Reagan Barnett, Sante Gnerre, Jason Willis, Michael J. Overman, Kanwal Pratap Singh Raghav, Christine Megerdichian Parseghian, Arvind Dasari, Maria Pia Morelli, Benny Johnson, Madhulika Eluri, Leylah Drusbosky, Scott Kopetz, Van K. Morris. ctDNA-based fusion detection for advanced colorectal cancer with a partner-agnostic assay. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
10. Abhineet Uppal, Michael White, George J. Chang, Fadl A. Zeineddine, Mohamamd A. Zeineddine, Abdelrahman M.G. Yousef, Christopher Scally, Keith F. Fournier, Timothy E. Newhook, Y. Nancy You, Jason Willis, Scott Kopetz, John Paul Y.C. Shen. Tumor mutations associated with outcomes in colorectal peritoneal metastases. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
11. Mohamed E. Salem, Scott Kopetz, Josep Tabernero, Frank A. Sinicrope, Myriam Chalabi, Jeanne Tie, Kunal C. Kadakia, Thomas J. George, Elizabeth Mauer, Lisa Macera, Calvin Y. Chao, Sara Lonardi, Eric Van Cutsem, Thierry Andre, Michael J. Overman. Comprehensive characterization of KRAS mutations and inter-relation with primary tumor location in colorectal cancers. J Clin Oncol 41(suppl 4), 2023.
12. Christopher Hanyoung Lieu, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Sahin, Dustin A. Deming, Philip Agop Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, Arvind Dasari. NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
13. Michael J. Overman, Greg Yothers, Samuel A. Jacobs, Hanna Kelly Sanoff, Deirdre Jill Cohen, Katherine A Guthrie, Norah Lynn Henry, Patricia A. Ganz, Scott Kopetz, Peter C. Lucas, Charles David Blanke, Theodore S. Hong, Norman Wolmark, Howard S. Hochster, Thomas J. George, Caio Max Sao Pedro Rocha Lima. NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
14. Stacey A. Cohen, Pashtoon Murtaza Kasi, Vasily N. Aushev, Diana L. Hanna, Gregory P. Botta, Saima Sharif, Georgios I. Laliotis MD, PhD, Vivek R. Sharma, Ali Alqahtani, Sreenivasa R Chandana, Sandra Kang, Sakti Chakrabarti, Bradley G. Somer, Anup Kasi, Farshid Dayyani, Midhun Malla, Adham A Jurdi, Minetta C. Liu, Alexey Aleshin, Scott Kopetz. Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
15. J. Randolph Hecht, Scott Kopetz, Theodore Welling, Maria Pia Morelli, Julian R. Molina, Kedar Kirtane, Paul Eliezer Oberstein, Daniel R. Greenwald, Yi Lin, Armen Mardiros, Karl Beutner, Ariane Lozac'hmeur, Ameen Salahudeen, Kirstin B. Liechty, Judy Vong, Eric Wai-Choi Ng, David G. Maloney, William Y. Go, John Sutton Welch, Diane M. Simeone. Prospective BASECAMP-1 experience in patients with gastrointestinal (GI) cancer: Identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for a future therapeutic trial exploiting LOH as a tumor vulnerability. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
16. Kanwal Pratap Singh Raghav, Katherine A Guthrie, Scott Kopetz, Benjamin R. Tan, Crystal S. Denlinger, Marwan Fakih, Michael J. Overman, Arvind Dasari, Larry R. Corum, Lee G. Hicks, Mital Patel, Benjamin T Esparaz, Syed Mohammad Ali Kazmi, Nitya Alluri, Sarah Colby, Sepideh Gholami, Philip Jordan Gold, E. Gabriela Chiorean, Howard S. Hochster, Philip Agop Philip. A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
17. Scott Kopetz, Tanios S. Bekaii-Saab, Takayuki Yoshino, Chin-Hee Chung, Xiaosong Zhang, Josep Tabernero. SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E–mutant microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023.
18. Archana Gopalan; Thomas D. Gallup; Stephanie Wood; Jose Maldonado; Corina Margain; Nestor F. Esnaola; Min P. Kim; E. Scott Kopetz; Kyuson Yun. A novel 3D culture platform for precision medicine. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022.
19. Anil Korkut; Xubin Li; Elizabeth Kong; Gonghong Yan; Zeynep Dereli; Behnaz Bozorgui; Parisa Imanirad; Jacob Elnaggar; Augustin Luna; David Menter; Patrick Pilié; Timothy Yap; Scott Kopetz; Chris Sander. Precision combination therapies based on recurrent oncogenic co-alterations. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022.
20. Heinz-Josef Lenz; Hanz Prenen; Eric Van Cutsem; Thibaud Kössler; Jean-François Mayol; Francesca Trapani; Matthieu Tihy; Laura Rubbia-Brandt; Christian Toso; Thomas Bogenrieder; Elodie Belnoue; Madiha Derouazi; Scott Kopetz. ATP128 vaccine with ezabenlimab promotes antigen-specific immune responses in stage IV colorectal cancer in the KISIMA-01 phase 1b trial. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022.
21. Hey Min Lee; Stefania Napolitano; Alexy Sorokin; Melanie N. Woods; Saikat Chowdhury; Jumanah Y. Alshenaifi; Anand K. Singh; John Paul Shen; Funda Meric-Bernstam; Kunal Rai; Scott Kopetz. Bromodomain and extraterminal (BET) protein inhibition sensitize BRAFV600E colorectal cancer to standard targeted therapies. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022.
22. Sha'Kayla K. Nunez; Corey D. Young; Ti'ara L. Griffen; Scott Kopetz; James W. Lillard. Co-expressed gene networks in CRC CMS1 subtype. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022.
23. Heinz-Josef Lenz; Thibaud Koessler; Paul Oberstein; Eric Van Cutsem; Sunnie Kim; Ralph Fritsch; Hans Prenen; Michael Morse; Delphine Gani; Madiha Derouazi; Thomas Bogenrieder; Scott Kopetz. KISIMA-01: A first-in-human trial of the heterologous prime-boost vaccine ATP128/VSV-GP128 with ezabenlimab (BI 754091) in patients with stage IV colorectal cancer. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022.
24. Sajid Khan; Janet Wiegand; Peiyi Zhang; Wanyi Hu; Dinesh Thummuri; Vivekananda Budamagunta; Nan Hua; Lingtao Jin; Carmen J. Allegra; Edmund S. Kopetz; Maria Zajac-Kaye; Frederic J. Kaye; Guangrong Zheng; Daohong Zhou. A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022.
25. Irene C. Waizenegger; Hengyu Lu; Claus Thamer; Fabio Savarese; Daniel Gerlach; Dorothea Rudolph; Christopher P. Vellano; Marcelo Marotti; John Heymach; Scott Kopetz; Timothy P. Heffernan; Joseph R. Marszalek; Mark P. Petronczki; Marco H. Hofmann; Norbert Kraut. Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022.
26. Saikat Chowdhury; Ria Gupta; Valsala Haridas; Mohammad A. Zeineddine; Scott Kopetz; John Paul Shen. Consensus molecular subtypes (CMS) of colorectal cancer predict anti-EGFR response irrespective of tumor sidedness. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022.
27. Darlan Conterno Minussi; Junke Wang; Aislyn Schalck; Yun Yan; Hua-Jun Wu; Cheng Peng; Min Hu; Emi Sei; Mary Edgerton; Hui Chen; Alejandro Contreras; David Hui; Senthil Damodaran; Scott Kopetz; Bora Lim; Nicholas Navin. Resolving clonal substructure from single cell genomic data in primary and metastatic tumors using CopyKit. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022.
28. Mohamed A. Gouda; Dzifa Y. Duose; Morten Lapin; Stephanie Zalles; Helen J. Huang; Yuanxin Xi; Xiaofeng Zheng; Amira I. Aldesoky; Alshimaa M. Alhanafy; Mohamed A. Shehata; Jing Wang; Scott Kopetz; Funda Meric-Bernstam; Ignacio I. Wistuba; Rajyalakshmi Luthra; Filip Janku. Mutation-agnostic detection of colorectal cancer-specific cell-free DNA using targeted methylation sequencing. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022.
29. Scott Kopetz, Tanios S. Bekaii-Saab, Takayuki Yoshino, Chin-Hee Chung, Xiaosong Zhang, Josep Tabernero. SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022.
30. Scott Kopetz, Van K. Morris, Bert O'Neil, John A. Bridgewater, Janet Graham, Eileen E. Parkes, Mark P. Saunders, Elspeth Asken, Louise Goodwin, Caroline Phillips, Jane Robertson, Craig Tilston, Simon Woodcock, Natalie Cook. A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022.
31. Scott Kopetz, Van K. Morris, Vicente Alonso-Orduña, Pilar Garcia-Alfonso, Margarita Reboredo, Ana Fernandez Montes, Joan Maurel, David Paez, Anke C. Reinacher-Schick, Thomas Höhler, Javier Carrasco, Barbara Marie Galligan, Luisa Manning, Liane Preußner, Özlem Tureci, Ugur Sahin. A phase 2 multicenter, open-label, randomized, controlled trial in patients with stage II/III colorectal cancer who are ctDNA positive following resection to compare efficacy of autogene cevumeran versus watchful waiting. J Clin Onco 2022 ASCO Annual Meeting 40(supply 16), 2022.
32. Scott Kopetz, Danielle A. Murphy, Jie Pu, Rona Yaeger, Fortunato Ciardiello, Jayesh Desai, Eric Van Cutsem, Harpreet Singh Wasan, Takayuki Yoshino, Elena Elez, Adele Golden, Zhou Zhu, Xiaosong Zhang, Josep Tabernero. Evaluation of baseline BRAF V600E mutation in circulating tumor DNA and efficacy response from the BEACON study. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022.
33. Scott Kopetz, Takayuki Yoshino, Tae Won Kim, Jayesh Desai, Rona Yaeger, Eric Van Cutsem, Fortunato Ciardiello, Harpreet Singh Wasan, Tim Maughan, Yuanyuan Zhang, Tiziana Usari, Chin-Hee Chung, Xiaosong Zhang, Josep Tabernero. BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022.
34. Scott Kopetz, Axel Grothey, Rona Yaeger, Fortunato Ciardiello, Jayesh Desai, Tae Won Kim, Tim Maughan, Eric Van Cutsem, Harpreet Singh Wasan, Takayuki Yoshino, Michelle L. Edwards, Adele Golden, Ashwin Gollerkeri, Josep Tabernero. BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022.
35. S. Kopetz. ctDNA as a Tool to Detect Minimal Residual Disease After Surgery. 2022 ASCO Gastrointestinal Cancers Symposium, 2022.
36. Benny Johnson, Scott Kopetz, Hyunsoo Hwang, Ying Yuan, Ronald Anthony DePinho, John Zebala, Michael J. Overman. STOPTRAFFIC-1: A phase I/II trial of SX-682 in combination with nivolumab for refractory RAS-mutated microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022.
37. Benny Johnson, Dong Yang, Hiba I. Dada, Leylah Drusbosky, Scott Kopetz. Comprehensive landscape of BRAF variant classes, clonalities, and comutations in metastatic colorectal cancer using ctDNA profiling. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022.
38. Kanwal Pratap Singh Raghav, Fang-Shu Ou, Alan P. Venook, Federico Innocenti, Ryan Sun, Heinz-Josef Lenz, Scott Kopetz. Circulating tumor DNA dynamics on front-line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: A biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022.
39. Aung Naing, Hirva Mamdani, Minal A. Barve, Melissa Lynne Johnson, Daniel Morgensztern, Anthony J. Olszanski, Robert A. Wolff, Shubham Pant, Marya F. Chaney, Tolani Adebanjo, Jean Fan, Richard D. Kim, Scott Kopetz. Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study. J Clin Onco 2022 ASCO Annual Meeting 40(suppl 16), 2022.
40. Mohamed E. Salem, Scott Kopetz, Sherif Mohamed El-Refai, Josep Tabernero, Frank A. Sinicrope, Jeanne Tie, Thomas J. George, Eric VanCutsem, Elizabeth Mauer, Sara Lonardi, Thierry Andre, Michael J. Overman, David Foureau. Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E-mutated versus MSI-H BRAF wild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immunometabolomic biomarkers. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022.
41. Mohamed E. Salem, Thierry Andre, Sherif Mohamed El-Refai, Scott Kopetz, Josep Tabernero, Frank A. Sinicrope, Jeanne Tie, Thomas J. George, Eric VanCutsem, Elizabeth Mauer, Sara Lonardi, Michael J. Overman, David Foureau. Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC). J Clin Onco 2022 ASCO Annual Meeting 40(suppl 16), 2022.
42. Marcelo Vailati Negrao, Maria Pia Morelli, Amir A. Jazaeri, Benny Johnson, Partow Kebriaei, Drew Deninger, Eleanor De Groot, Matthew R. Collinson-Pautz, Nathan A. Demars, Jaymes S. Holland, John Heymach, Raffaele Baffa, Scott Kopetz. First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022.
43. Maliha Nusrat, Muddassir Ali Syed, Riham Katkhuda, Edwin R. Parra, Ignacio Ivan Wistuba, Paul Kong, Amanda Koehne, Arvind Dasari, Michael J. Overman, David Menter, Scott Kopetz. The immune impact of PI3K-AKT pathway inhibition in colorectal cancer. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022.
44. Arvind Dasari, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Sahin, Dustin A. Deming, Philip Agop Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Norman Wolmark, Greg Yothers, Thomas J. George, Christopher Hanyoung Lieu. Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008. J Clin Onco 2022 ASCO Annual Meeting 40(suppl 16), 2022.
45. Deepak Bhamidipati, Kanwal Pratap Singh Raghav, Van K. Morris, Scott Kopetz, Bryan K. Kee, Benny Johnson, Jason Willis, Arvind Dasari, Maria Pia Morelli, Christine Megerdichian Parseghian, Michael Sangmin Lee, Phat Le, John Paul Y.C. Shen, Kaysia Ludford, Michael J. Overman. Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl), 2022.
46. Kristen Simmons, Bryan K. Kee, Kanwal Pratap Singh Raghav, Benny Johnson, Scott Kopetz, Jason Willis, Arvind Dasari, Eduardo Vilar Sanchez, Kaysia Ludford, Christine Megerdichian Parseghian, Michael Sangmin Lee, Phat Le, John Paul Y.C. Shen, Michael J. Overman, Van K. Morris. Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022.
47. Michael Sangmin Lee, Tyler J. Zemla, Kristen Keon Ciombor, Autumn Jackson McRee, Mehmet Akce, Shaker R. Dakhil, Brandy L. Jaszewski, Fang-Shu Ou, Tanios S. Bekaii-Saab, Scott Kopetz. A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic KRAS/NRAS mutant (mut) colorectal cancer (CRC). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022.
48. Alisha Heather Bent, Dipen M. Maru, Jean-Nicolas Vauthey, Arvind Dasari, Benny Johnson, Bryan K. Kee, Christine Megerdichian Parseghian, David Menter, Michael J. Overman, Van K. Morris, Pang-Dian Fan, Kumiko Koyama, Naoyuki Maeda, Scott Kopetz, Kanwal Pratap Singh Raghav. HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022.
49. Christine Megerdichian Parseghian, Eduardo Vilar Sanchez, Ryan Sun, Madhulika Eluri, Van K. Morris, Benny Johnson, Maria Pia Morelli, Michael J. Overman, Jason Willis, Ryan Huey, Kanwal Pratap Singh Raghav, Arvind Dasari, Bryan K. Kee, Robert A. Wolff, John Paul Y.C. Shen, Scott Kopetz. Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer. J Clin Oncol 40(suppl. 16), 2022.
50. Arvind Dasari, Maen Abdelrahim, Jared David Acoba, Krishna Chaitanya Alluri, Tomislav Dragovich, Syed Mohammad Ali Kazmi, Benjamin Leon Musher, Ryan Sun, Lucas Wong, Y. Nancy You, Robert Anthony Zaiden, Scott Kopetz. Minimal residual disease assessment in colorectal cancer (MiRDA-C). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022.
51. Christine Megerdichian Parseghian, Ryan Sun, Melanie Nicole Woods, Stefania Napolitano, Jumanah Alshenaifi, Jason Willis, ShaKayla Kentel Nunez, Alexey Sorokin, Preeti Kanikarla Marie, Kanwal Pratap Singh Raghav, Van K. Morris, John Paul Y.C. Shen, Eduardo Vilar Sanchez, Marko Rehn, Agnes Ang, Teresa Troiani, Scott Kopetz. Resistance mechanisms to anti-EGFR therapy in RAS/RAF wildtype colorectal cancer varies by regimen and line of therapy. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022.
52. Jonathan M. Loree, James T. Topham, Hagen Fritz Kennecke, Harriet Feilotter, Young S Lee, Shakeel Virk, Scott Kopetz, Dzifa Yawa Duose, Ganiraju C. Manyam, Jeffrey S Morris, Dipen M. Maru, Daniel Renouf, Derek J. Jonker, Dongsheng Tu, Christopher J. O'Callaghan, Eric Xueyu Chen. Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC). J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022.
53. Arvind Dasari, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Halil Sahin, Dustin A. Deming, Philip Agop Philip, Theodore S. Hong, Norman Wolmark, Greg Yothers, Thomas J. George, Christopher Hanyoung Lieu. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022.
54. Van K. Morris, Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal, Patrick M Boland, Dustin A. Deming, Aaron James Scott, Howard John Lim, Theodore S. Hong, Norman Wolmark, Thomas J. George. Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022.
55. Van K. Morris, Christine Megerdichian Parseghian, Michelle Escano, Benny Johnson, Kanwal Pratap Singh Raghav, Arvind Dasari, Ryan Huey, Michael J. Overman, Jason Willis, Michael Sangmin Lee, Robert A. Wolff, Bryan K. Kee, Phat Le, Cori Margain, Dave Gallup, Alda Tam, Wai Chin Foo, Lianchun Xiao, Kyuson Yun, Scott Kopetz. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022.
56. Benny Johnson, Dong Yang, Hiba I. Dada, Van K. Morris, Xuemei Wang, Arvind Dasari, Kanwal Pratap Singh Raghav, Bryan K. Kee, John Paul Y.C. Shen, Ryan Huey, Michael Sangmin Lee, Christine Megerdichian Parseghian, Phat Le, Maria Pia Morelli, Jason Willis, Robert A. Wolff, Leylah Drusbosky, Michael J. Overman, Scott Kopetz. RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022.
57. Rodabe Navroze Amaria, David J. Vining, Scott Kopetz, Michael J. Overman, Milind M. Javle, Mara Antonoff, Ching-Wei D. Tzeng, Robert A. Wolff, Shubham Pant, Kathryn Lito, Kelly M. Rangel, Louis Wilson, Bryan M. Fellman, Cara L. Haymaker, Ying Yuan, Marie-Andree Forget, Patrick Hwu, Chantale Bernatchez, Amir A. Jazaeri. Efficacy and safety of autologous expanded tumor infiltrating lymphocytes (TILs) in multiple solid tumors. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022.
58. Caio Max Sao Pedro Rocha Lima, Greg Yothers, Samuel A. Jacobs, Hanna Kelly Sanoff, Deirdre Jill Cohen, Katherine A Guthrie, Norah Lynn Henry, Patricia A. Ganz, Scott Kopetz, Peter C. Lucas, Charles David Blanke, Theodore S. Hong, Norman Wolmark, Howard S. Hochster, Thomas J. George, Michael J. Overman. Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022.
59. Oscar Villarreal, Fadl A. Zeineddine, Ray Chacko, Christine Megerdichian Parseghian, Benny Johnson, Jason Willis, Michael Sangmin Lee, Van K. Morris, Arvind Dasari, Kanwal Pratap Singh Raghav, Michael J. Overman, Y. Nancy You, Yinghong Wang, Dipen M. Maru, John Paul Y.C. Shen, Scott Kopetz. Outcomes of IBD-associated colorectal cancer and implications in early-onset colorectal cancer. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022.
60. Diane M. Simeone, J. Randolph Hecht, Sandip Pravin Patel, Maria Pia Morelli, Kedar Kirtane, Mitesh J. Borad, Marcela Valderrama Maus, John B. Sunwoo, Theodore Welling, Yi Lin, Edward B. Garon, Scott Kopetz, Frederick L. Locke, Kirstin B. Liechty, Ariane Lozac'hmeur, Karl Beutner, Eric Wai-Choi Ng, William Y. Go, David G. Maloney, Julian R. Molina. BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022.
61. Caio Max Sao Pedro Rocha Lima, Greg Yothers, Samuel A. Jacobs, Hanna Kelly Sanoff, Deirdre Jill Cohen, Katherine A Guthrie, Norah Lynn Henry, Patricia A. Ganz, Scott Kopetz, Peter C. Lucas, Charles David Blanke, Norman Wolmark, Howard S. Hochster, Thomas J. George, Michael J. Overman. NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022.
62. J. Randolph Hecht, Scott Kopetz, Sandip Pravin Patel, Theodore Welling, Maria Pia Morelli, Mitesh J. Borad, Julian R. Molina, Kedar Kirtane, Yi Lin, Michelle Fan-Port, Armen Mardiros, Karl Beutner, Ariane Lozac'hmeur, Denise Lau, Kirstin B. Liechty, Judy Vong, Eric Ng, David G. Maloney, William Y. Go, Diane M. Simeone. Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022.
63. Oluwadara Coker; Alexey Sorokin; Kelly Gale; Fengqin Gao; John Paul Shen; Lawrence Kwong; Ji Wu; Hey Min Lee; Melanie Woods; Oscar Villareal; Scott Kopetz. Oncogenic KRASG12C dependency in colorectal cancer. Cancer Res 2021 American Association for Cancer Research 81(suppl 13), 2021.
64. Xiaotao Zhang; Kristi L. Hoffman; Fangyu Li; Ehsan Irajizad; Gladys Browman; Karen Basen-Engquist; Samir Hanash; Paul Scheet; Pablo C. Okhuysen; Scott Kopetz; Joseph Petrosino; Carrie R. Daniel. Beans to Enrich the Gut microbiome vs. Obesity's Negative Effects: First results from the BE GONE Trial in high-risk colorectal patients. Cancer Res 2021 American Association for Cancer Research 81(suppl 13), 2021.
65. Fangyu Li; Michael G. White; Jennifer Davis; Kristi L. Hoffman; David Menter; Nadim Ajami; Xiaotao Zhang; Jeffrey S. Morris; Robert R. Jenq; Joseph Petrosino; Jennifer A. Wargo; Scott Kopetz; Carrie R. Daniel. Tumor microbiota profiles are associated with molecular subtype and survival in colorectal cancer patients. Cancer Res 2021 American Association for Cancer Research 81(suppl 13), 2021.
66. Van K. Morris, Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal, Patrick M Boland, Dustin A. Deming, Aaron James Scott, Howard John Lim, Norman Wolmark, Thomas J. George. Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA). J Clin Oncol 2021 Gastrointestinal Cancers Symposium 39(suppl 3), 2021.
67. Scott Kopetz, Axel Grothey, Fortunato Ciardiello, Jayesh Desai, Tae Won Kim, Tim Maughan, Eric Van Cutsem, Harpreet Singh Wasan, Rona Yaeger, Takayuki Yoshino, Ashwin Gollerkeri, Michelle Edwards, Montessa Rodriguez Lizaso, Josep Tabernero. Global BRAF testing practices in metastatic colorectal cancer. J Clin Oncol 2021 Gastrointestinal Cancers Symposium 39(3_suppl), 2021.
68. Van K. Morris, Michael Lam, Xuemei Wang, Michael J. Overman, Benny Johnson, Bryan K. Kee, Robert A. Wolff, Arvind Dasari, Isabel R. Zorrilla, Alda Tam, Dipen M. Maru, Scott Kopetz. Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy. J Clin Onco 2021 Gastrointestinal Cancers Symposium 39(3_suppl), 2021.
69. Kanwal Pratap Singh Raghav, Takayuki Yoshino, Hiroya Taniguchi, Sabine Tejpar, Arndt Vogel, Zev A. Wainberg, Kensei Yamaguchi, Masayuki Kanai, Yali Liu, Sabeen Mekan, Geetha Pudussery, Yang Qiu, Scott Kopetz. An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC). J Clin Onco 2021 Gastrointestinal Cancers Symposium 39((suppl 3), 2021.
70. Hey Min Lee, Stefania Napolitano, Van K. Morris, Kunal Rai, John Paul Y.C. Shen, Jennifer S. Davis, Dipen M. Maru, Michael J. Overman, Ji Wu, Oluwadara Coker, Melanie Nicole Woods, Oscar Villarreal, Scott Kopetz. Epigenetic regulation of the Wnt-signaling pathway in CIMP-H BRAFV600E mCRC. J Clin Onco 2021 Gastrointestinal Cancers Symposium 39(suppl. 3), 2021.
71. Nicolette Taku, Y. Nancy You, Ethan B. Ludmir, Grace L. Smith, Miguel A. Rodriguez-Bigas, George J. Chang, John Michael Skibber, Albert C. Koong, Bruce D. Minsky, Emma Brey Holliday, Eugene Jon Koay, Arvind Dasari, Cullen M. Taniguchi, Brian K. Bednarski, Van K. Morris, Michael J. Overman, Scott Kopetz, Kanwal Pratap Singh Raghav, Prajnan Das. Clinical outcomes following definitive treatment of young-onset, locally advanced rectal cancer: A single institution experience. J Clin Oncol 2021 ASCO Annual Meeting 39(suppl. 15), 2021.
72. Junhua Yu, Kanwal Pratap Singh Raghav, Aparna Raj Parikh, David Hanna, Enrique Marino, Victoria M. Raymond, Rebecca Nagy, Nicole Zhang, Ryan Bruce Corcoran, Scott Kopetz, John H. Strickler, Kathryn Lang. Real-world genomic and treatment landscape in advanced colorectal cancer identifies treatment differences pre- and post-ctDNA genomic profiling. J Clin Oncol 2021 Gastrointestinal Cancers Symposium 39(suppl. 3), 2021.
73. Ecaterina E. Ileana Dumbrava; Helen J. Huang; Ana Stuckett; Kiran Madwani; Abha Adat; David S. Hong; Sarina A. Piha-Paul; Vivek Subbiah; Daniel D. Karp; Siqing Fu; Aung Naing; Apostolia M. Tsimberidou; Stacey Moulder; Kimberly Koenig; Carlos H. Barcenas; Bryan Kee; David Fogelman; Scott Kopetz; Funda Meric-Bernstam; Filip Janku. PIK3CA mutations in plasma cell-free DNA predict survival and treatment outcomes in patients with advanced cancers. Mol Cancer Res 2020 American Association for Cancer Research 18(suppl 10), 2020.
74. Maliha Nusrat; David Hong; Sarina A. Piha-Paul; Vivek Subbiah; Jordi Rodon; Apostolia Tsimberidou; Abha Adat; Yan Wang; Michael Overman; Scott Kopetz; Funda Meric-Bernstam; Filip Janku. Activating mutations of phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene confer sensitivity to PD-L1 checkpoint inhibition in metastatic adenocarcinoma patients. Mol Cancer Res 2020 American Association for Cancer Research 18(suppl 10), 2020.
75. Jennifer Sarah Davis; Preeti Kanikarla; Patrick L. Yu; Mihai Gagea; Dexing Fang; Manu Sebastian; Peiying Yang; Ernest Hawk; Roderick Dashwood; Lenard M. Lichtenberger; David Menter; Scott Kopetz. Sulindac plus phospholipid is effective for polyp reduction and safer than sulindac alone. Cancer Res 2020 American Association for Cancer Research 80(suppl 16), 2020.
76. Nidhi Sahni; Daniel J. McGrail; Jeannine Garnett; Jun Yin; Hui Dai; David J. H. Shih; Guang Peng; David Menter; Melinda S. Yates; Scott Kopetz; Karen Lu; Russell Broaddus; Gordon B. Mills; Shiaw Y. Lin. Proteome instability is an immunogenic therapeutic vulnerability in mismatch repair deficient cancer. Cancer Res 2020 American Association for Cancer Research 80(suppl 16), 2020.
77. Deepak Bhamidipati; Anuj Verma; Dipen M. Maru; Dawen Sui; Grace Mathew; Wenhua Lang; Juan F. Posadas; Joshua P. Hein; Scott Kopetz; Andrew Futreal; Ignacio I. Wistuba; J. Jack Lee; Michael J. Overman; Alda L. Tam. Analysis of 1151 prospective research biopsies: Factors influencing tumor yield across patients and biopsy cores. Cancer Res 2020 American Association for Cancer Research 80(suppl 16), 2020.
78. Kopetz S, Litzenburger B, Kinyua W, Sajan B, Subbiah V, Zinner R, Wheler JJ, Hong DS, Tsimberidou AM, Overman MJ, Pagliaro LC, Busaidy NL, Westin SN, Glisson BS, Heymach J, Meric-Bernstam F, Shaw KR, Lee JJ, Broaddus R. Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment. J Clin Oncol 33(suppl), 2015.
79. Overman MJ, Kee BK, Fogelman DR, Eng C, Vilar Sanchez E, Shroff RT, Dasari A, Wolff RA, Morris J, Kopetz S. A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer. J Clin Oncol 33(suppl), 2015.
80. Morelli MP, Overman MJ, Kee BK, Vilar Sanchez E, Morris VK, Fogelman DR, Janku F, Garrett CR, Shureiqi I, Raghav KPS, Eng C, Manuel S, Wolff RA, Eltoukhy H, Lanman RB, Talasaz AA, Kopetz S. Predictors of clonal evolution in metastatic colorectal cancer patients. J Clin Oncol 33(suppl), 2015.
81. Bedard PL, Davies MA, Kopetz S, Flaherty KT, Shapiro G, Luke JJ, Spreafico A, Wu B, Gomez C, Cartot-Cotton S, Mazuir F, Micallef S, Demers B, Juric D. First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737). J Clin Oncol 33(suppl), 2015.
82. Morris VK, Morelli MP, Janku F, Overman MJ, Kee BK, Fogelman DR, Vilar Sanchez E, Shureiqi I, Garrett CR, Raghav KPS, Eng C, Manuel S, Wolff RA, Eltoukhy H, Lanman RB, Talasaz AA, Kopetz S. Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients. J Clin Oncol 33(suppl), 2015.
83. Hong DS, Morris VK, El Osta BE, Fu S, Overman MJ, Piha-Paul SA, Subbiah V, Kee BK, Tsimberidou AM, Zinner R, Fogelman DR, Bellido J, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol 33(suppl), 2015.
84. Kwatampora L, Clarke C, Silva A, Zorba Y, Williams MD, Broaddus R, Clayman GL, El-Naggar AK, Gagel RF, Grubbs EG, Habra MA, I-Nan Hu M, Jimenez C, Kopetz S, Lee JE, StevSherman SI, Vassilopoulou-Sellin R, Waguespack S, Perrier ND, Busaidy NL. Recurrent parathyroid carcinoma and the need for molecular profiling to aid in prognostication and therapeutics. J Clin Oncol 33(suppl), 2015.
85. Meric-Bernstam F, Brusco L, Daniels MS, Strong LC, Shaw KR, Lu KH, Qi Y, Lara-Guerra H, Litton JK, Zhao H, Eterovic AK, Arun B, Routbort M, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. J Clin Oncol 33(suppl), 2015.
86. Janku F, Vibat CRT, Falchook GS, Huang HJ, Hong DS, Piha-Paul SA, Subbiah V, Ramzanali NM, Hancock S, Naing A, DaKarp DD, Nitti G, Cabrilo G, Luthra R, Patel SP, Overman MJ, Kopetz S, Erlander MG, Melnikova V, Meric-Bernstam F. Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers. J Clin Oncol 33(suppl), 2015.
87. Lee MS, Clarke C, Jiang ZQ, Manyam GC, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Shureiqi I, Raghav KPS, Eng C, Chang GJ, Simon I, Bernards R, Mills GB, Overman MJ, Maru DM, Kopetz S. Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups independent of oncogenic mutations. J Clin Oncol 33(suppl 3), 2015.
88. Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Hartmann A, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10(1):205. e-Pub 2012. PMID: 23034130.
89. Kopetz S, Lemos R, Powis G. The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men. Clinical Cancer Research, 2012.
90. Corcoran RB, Falchook GS, Infante JR, Hamid O, Messersmith WA, Kwak EL, Ryan DP, Kurzrock R, Brenner AA, Luan J, Sun P, Allred AJ, Little SM, Patel L, Kopetz S, Venook AP. BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212). J Clin Oncol 30, 2012.
91. Overman MJ, Eng C, Kee BK, Fogelman DR, Fark C, Hippert R, Holter S, Issa JP, Hamilton SR, Kopetz S. A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer. J Clin Oncol 30, 2012.
92. Chen Z, Overman MJ, Garrett CR, Jiang ZQ, Wolff RA, Abbruzzese JL, Eng C, Kopetz S. Systematic survey of therapeutic trials for metastatic colorectal cancer. J Clin Oncol 30(suppl 4), 2012.
93. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, Maru D, Munsell MF, Clemons MV, Kopetz S, Garrett CR, Shureiqi I, Krishnan S, Delclos ME, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal adenocarcinoma: A phase I trial. J Clin Oncol 30(suppl 4), 2012.
94. Shah NN, Lieu CH, Ivan C, Overman MJ, Shimizu M, Morris J, Tran H, Heymach J, Calin G, Kopetz S. Prognostic effects of circulating markers of epithelial mesenchymal transition (EMT) in metastatic colorectal cancer patients. J Clin Oncol, 2012.
95. Overman MJ, George B, Kalil K, Ferrarotto R, Eng C, Garrett CR, Loyer E, Hoff PM, Charnsangavej C, Kopetz S. Use of bevacizumab to reduce the rate of oxaliplatin-induced thrombocytopenia and splenomegaly. J Clin Oncol 30(Suppl 4), 2012.
96. Raghav KPS, Kalil K, Ferrarotto R, George B, Eng C, Garrett CR, Loyer E, Hoff PM, Charnsangavej C, Kopetz S, Overman MJ. Effect of bevacizumab on rate of oxaliplatin-induced thrombocytopenia and splenomegaly. J Clin Oncol 30, 2012.
97. Chen ZY, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong DS, Hoff PM, Tran HT, Heymach J, Overman MJ, Kopetz S. Correlation of specific cytokine profiles with high blood neutrophil-to-lymphocyte ratio and outcome in metastatic colorectal cancer. J Clin Oncol 30, 2012.
98. Chang GJ, Park IJ, Eng C, You YN, Kopetz S, Overman MJ, Rodriguez-Bigas MA, Skibber JM. Exploratory analysis of adjuvant chemotherapy benefits after preoperative chemoradiotherapy and radical resection for rectal cancer. J Clin Oncol 30, 2012.
99. Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru DM, Elvin D, Kopetz S, Gallick GE. Relationship of Src activity and prior oxaliplatin on outcomes after hepatectomy for metastatic colorectal cancer. J Clin Oncol 30, 2012.
100. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey J, Rodriguez-Bigas MA, Curley SA, Feig BW. Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab (BV) for colorectal cancer (CRC) liver metastases. 2007 Gastrointestinal Cancers Symposium, 2012.
101. Mao M, Tsao L, Dayyani F, Gopal V, Nanda Y, Mills G, Bollag G, Davies M, Gallick G, Kopetz S. Resistance to BRAF inhibition in BRAF V600E colorectal cancer is associated with PI3K/AKT activation and hypermethylation. AACR 2011:LB-228, 2011.
102. Lieu CH, Tran HT, Fiorentino S, Jiang Z, Mao M, Overman MJ, Eng C, Ellis LM, Heymach J, Kopetz S. Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer. J Clin Oncol 29((suppl 4; abstr 401)), 2011.
103. Jiang Z, Mehta TR, You YN, Chang GJ, Eng C, Overman MJ, Maru M, Hamilton SR, Kopetz S. Association of PTEN loss and local recurrence in stage II-III colon cancer. J Clin Oncol 29((suppl 4; abstr 399)), 2011.
104. Kopetz S, Tran HT, Cunningham D, Mookerjee B, Pike L, Jurgensmeier J, Heymach J. Association of circulating cytokine and angiogenic factors (CAFs) with outcomes to second-line FOLFOX plus bevacizumab or cediranib in metastatic colorectal cancer. J Clin Oncol 29((suppl 4; abstr 406)), 2011.
105. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM). J Clin Oncol 29((suppl 4; abstr 507)), 2011.
106. George B, You Y, Viswanathan C, Wen S, Baladandayuthapani V, Overman MJ, Kee BK, Kopetz S, Eng C, Garrett CR. Survival advantage associated with palliative oophorectomy in patients with metastatic colorectal cancer (CRC) to the ovaries (mCRC-O): A single institution retrospective analysis. J Clin Oncol 29((suppl 4; abstr 539)), 2011.
107. Ferrarotto R, Machado KK, Mak MP, Vieira VA, Takahashi TK, Saragiotto DF, Kopetz S, Overman MJ, Hoff PM. A multicenter, multinational retrospective analysis of mitomycin C (MMC) in refractory metastatic colorectal cancer (mCRC). J Clin Oncol 29, 2011.
108. Lieu CJ, Tran HT, Fiorentino S, Jiang Z, Mao M, Overman MJ, Eng C, Ellis LM, Heymach J, Kopetz S. Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer. J Clin Oncol 29, 2011.
109. Hassabo HM, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM). J Clin Oncol 29, 2011.
110. Lieu CH, Tran HT, Jiang Z, Mao M, Overman MJ, Eng C, Morris J, Ellis LM, Heymach J, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. J Clin Oncol 29, 2011.
111. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM). J Clin Oncol 29, 2011.
112. Jiang Z, Mehta TR, You YN, Chang GJ, Eng C, Overman MJ, Maru D, Hamilton SR, Kopetz S. Association of PTEN loss and local recurrence in stage II-III colon cancer. J Clin Oncol 29, 2011.
113. George B, Estrella J, Machado L, Ferrarotto R, Hoff PM, Rashid A, Kopetz S. High-grade neuroendocrine carcinomas (HGNECs) of the colon and rectum: A single-institution retrospective analysis. J Clin Oncol 29, 2011.
114. George B, You YN, Viswanathan C, Wen S, Baladandayuthapani V, Overman MJ, Kee BK, Kopetz S, Eng C, Garrett CR. Survival advantage associated with palliative oophorectomy in patients with metastatic colorectal cancer (CRC) to the ovaries (mCRC-O): A single institution retrospective analysis. J Clin Oncol 29, 2011.
115. Chang G, Maru D, Agarwal A, Schlette E, Wolff R, Rodriguez-Bigas M, You N, Feig B, Kopetz S, Skibber J, Eng C. Histopathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone. Annals of Oncology, 2010.
116. Chang G, Maru D, Agarwal A,Schlette E, Wolff R, Rodriguez-Bigas M, You N, Feig B, Kopetz S, Skibber J, Eng C.. Histopathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone. 12th World Congress on Gastrointestinal Cancer, 2010.
117. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee R.J., Nolop KB, Bhattacharya S, Saltz L.. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. ASCO 2010, 2010.
118. Tran B, Kopetz S, Tie Jeanne, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J.. Distinct Differences in Sites of Metastatic Disease May Contribute to Poorer Outcomes Observed in Patients with BRAF Mutant Colorectal Cancers. ASCO 2010, 2010.
119. Agarwal A, Kopetz S, Boonsirikamchai P, Chun YS, Wang H, Vauthey JN, Loyer EM, Maru DM.. Tumor Thickness at Tumor-Normal Interface (TNI): A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases (HCRM). United States and Canadian Academy of Pathology (USCAP), 2010.
120. Lieu CH, Wolff RA, Eng C, Overman MJ,Henry L, Coulson R, Garrett CR, Abbruzzese JL, Gallick GE, Kopetz S. Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. J Clin Oncol 28(7), 2010.
121. Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z, Lieu CH, Agarwal A, Maru D, Sieber O, Desai J. Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers. J Clin Oncol 28, 2010.
122. Boonsirikamchai P, Maru DM, Chun YS, Kaur H, Kopetz S, Loyer EM. New CT Findings of Response and Recurrence Independent of Change in Tumor Size in Colorectal Liver Metastasis Treated with Bevacizumab. presented at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Chicago, 2009.
123. Pozadzides K, Wang H, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Overman MJ. Immunophenotype and molecular characterization of small bowel adenocarcinoma. Gastrointestinal Cancers Symposium, 2009.
124. Kopetz S, Hoff P, Eng C, Overman MJ, Glover KY, Chang DZ, Wolff RA, Abbruzzese JL, Ellis LM, Heymach JV. Levels of angiogenic cytokines prior to disease progression in metastatic colorectal cancer patients treated with bevacizumab. Gastointestinal Cancers Symposium:292, 2009.
125. Chun YS, Kopetz S, Palavecino M, Zorzi D, Curley SA, Abdalla EK, Vauthey JN. Proposal of new staging in advanced colorectal cancer. Gastrointestinal Cancers Symposium:304, 2009.
126. Sankhala K, Takimoto C, Mita A, Xiong H, Rodon JA, Adinin R, Burns K, Toko T, Arakawa K, Kopetz S. Two Phase I, Pharmacokinetic (PK) and Pharmacodynamic (PD) Studies of TAS-109, a novel nucleoside analogue with 14 days and 7 days continuous infusion (CI) schedules. ASCO 2008, 2008.
127. Kopetz S, Wolff R, Eng C, Henry L, Glover K, Chang D, Overman M, Gallick G, Abbruzzese J.. Phase IB study of Src inhibitation with dasatinib in combination with 5-fluorouracil, leuvocorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer. AACR Meeting Abstracts:LB-69, 2008.
128. Eng C, Kopetz S, Morris J, Malik Z, Stewart D, Chang H, Ohinata A, Abbruzzese J, Gallick G.. Phase II study of the novel oral Src-kinase inhibitor, AZD0530, in previously treated advanced colorectal cancer patients. AACR Meeting Abstracts:LB-76, 2008.
129. Kopetz S. Phase I study of Src inhibition with dasatinib in combination with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer. 2008 ASCO Gastrointestinal Cancers Symposium, 2008.
130. Politano S, Pathak P, Hoff PM, Charnsangavej C, Overman MJ, Loyer E, Vauthey J, Wallace MJ, Wolff RA, Kopetz S.. The use of 5-fluorouracil and oxaliplatin (FOLFOX) for colorectal cancer is associated with the development of splenomegaly and thrombocytopenia. 2008 ASCO Annual Meeting, 2008.
131. Kopetz S, Mita MM, Sankhala KK, Moseley J, Sherman BM, Bradley CR, Tolcher AW.. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. 2008 ASCO Annual Meeting, 2008.
132. Kopetz S, Shah AN, Gallick GE. Src Continues Aging: Current and Future Clinical Directions. Clinical Cancer Research:7232, 2007.
133. Kopetz S, Wu J, Davies M, Parikh N, Johnson F, Gallick G, Donato N.. Synergistic activity of Src and EGFR inhibitors in colon cancer. AACR Annual Meeting, 2007.
134. Kopetz S. Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer. 2007 ASCO Annual Meeting, 2007.
135. Chang D, Zhu K, Kopetz S, Voo K, Li Y, Hwu P, Radvanyi L, Abbruzzese JL. Presence of survivin-specific cytotoxic T-lymphocytes (CTLs) in pancreatic cancer patients, and specific killing of human pancreatic carcinoma cells in vitro by survivin-specific CTLs. 2007 ASCO Annual Meeting, 2007.
136. Kopetz S, Wu J, Davies M, Johnson F, Donato N. Synergistic effects of combination therapy with anti-EGFR and anti-Src therapy in vitro in colon cancer. ASCO Gastrointestinal Cancers Symposium, 2007.
137. Kopetz S, Wu J, Johnson F, Donato N.. Anti-tumor effects of combination therapy with anti-EGFR and anti-Src therapy in colorectal cancer. AACR Meeting Abstracts:B51, 2006.
138. Kopetz S, Eng C, Adinin RB, Wolff RA, Lin E, Chang DZ, Abbruzzese JL, Hoff PM. Preliminary results from a phase II study of FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). 2006 World GI Congress, 2006.
139. Kopetz S, Eng C, Adinin R, Wolff RA, Lin E, Chang DZ, Abbruzzese JL, Hoff PM. Preliminary results from a phase II study of FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). 2006 ASCO Annual Meeting, 2006.
140. Kopetz S, Dang J, Overman M, Phan L, Feig B, Patel D, Wolff RA, Eng CA, Abbruzzese JL, Hoff P. Bevacizumab toxicity and efficacy are unaffected by regimen or resection status: A single institution retrospective study. Gastrointestinal Cancers Symposium, 2006.
141. Hoff PM, Eng C, Adinin RB, Wolff RA, Lin E, Kopetz S, Rodney A, Chang DZ, Abbruzzese JL. Preliminary results from a phase II study of FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). Gastrointestinal Cancers Symposium, 2006.
142. Dhillon N, Kopetz S, Del Fabbro E, Reddy S, Bruera E. The Establishment Of A Palliative Care Consult Team In A Comprehensive Cancer Center. 2005 ASCO Annual Meeting, 2005.

Book Chapters

1. Hong DS, Kopetz ES, George GC. Colorectal Cancer (Adenocarcinoma). In: Handbook of Targeted Cancer Therapy. Wolters Kluwer Health, 2015.
2. Bhadkamkar N, Crane CH, Rodriguez-Bigas M, Kopetz S, Eng C. Colorectal Cancer. In: The MD Anderson Manual of Medical Oncology. 2nd, 2011.
3. Hoff PMG, Kopetz S. Systemic Therapy for Non-operable Colorectal Cancer Metastases. In: Liver Metastases. Springer: United States of America, 51-8, 2008.
4. Kopetz S. Targeted Therapy in Cancer. In: Targeted Therapy for Colorectal Cancer. Humana Press: United States, 101-24, 2008.
5. Kopetz S, Hoff P. Management Issues in Patients Presenting with Stage IV Colorectal Cancer. In: Advanced Therapy in Surgical Oncology. Decker Press, 281-91, 2006.
6. Kopetz S, Raber M, Abbruzzese J. Colorectal, Anal, and Unknown Primary Cancer (electronic web update). In: Cancer Medicine, 2006.

Letters to the Editor

1. Vauthey JN, Zorzi D, Kopetz S, Abdalla EK, Kishi Y, Blazer DG, III. Reply to Colorectal hepatic metastases: adjuvant chemotherapy and survival by D. Gallagher et al. J Clin Oncol 27: e20-1, 2009.
2. Vauthey JN, Zorzi D, Kopetz S, Abdalla EK, Kishi Y, Blazer DG. Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival Reply. J Clin Oncol 27: E20-E21, 2009.
3. Kopetz S, Abbruzzese JL.. Hidden Biases in an Observational Study of Bevacizumab Beyond Progression. J Clin Oncol 27: 1732-3, 2009.
4. Overman M, Kopetz S. First-Line Therapeutic Strategies in Metastatic Colorectal Cancer The Davies/Goldberg Article Reviewed. Oncology, New York-New York 22: 1482-1483, 2008.